sultamicillin unasyn

'I . • :
:
••
"
I
1~f)'lilVtJ1Q
iJI.ij
11(;1~~mJl
3 l$ltJ'W .fJll(;111'Wl
12 i l Ill'!
tl.m~'hftli
'\U'('!'U(;11
f'IJ1J'j~111'Wl~\rtJVM llilv 11liihfl~f)
t1~H1'll~~'iJ'iJl'j~1Jf)~ llieJill
~'jl'iJ'il'!fllV VIS: BT 39°C, BP 90/60 mmHg,
PR 160/min, RR SO/min
Skin: generalized erythematous maculopapular rash, mild edema
of lower extremities s;1'!~1J
CBC Hb 12.6 gm/dL, Hct 37.0%, WBC 4,080 cells/cu.mm
(PMN 40%, L 49%, M 10%) platelet
J 76,000
/cu.mm
"
(~11HIl'J'l1'Wl
I
I
,ob'et: 1 X 3
H. pa"ainfluenzae
E. eoli
P~G'teus s~p.
@MEIACT
(cerdltoron
plvoxll)
R
kllelbsiella spp.
Salrmol'i\..ella ~pp.
SIilI,gella pp.
N. meningifidis
N. gOfilor:rtiloe..ae
pC
16)
Sultamicillin 250mg/5ml
Powder for Oral Suspension
•
.
'.
1 big spoonful
1 small spoonful
2.5 ml
10 ml
~'Ido, lur rJr
Itt 1Jflrr..Jgll
- IT'1f5""
Dose 25-50 mg/kg/day in 2 divided dose (For children dose
weight <30kg)
Cherry flavor is easily taken for children
After reconstitution can be stored in refrigerator up to 14 days
Unasyn :Sultamicillin is a double ester in which ampicillin and the beta lactamase inhibitor, sulbactam, are linked via
methylene group
Therapeutic indication: URTI, LRTI including sinusitis, otitis media and epiglottitis; bacterial pneumonias, UTI and
pyelonephritis; intra-abdominal infections, skin, soft tissue, bone and joint infection and gonococcal infections.
Dose recommendation: Sultamicillin in adult (including elderly patient) is 375-750mg twice daily. In children weighing
less than 30 kg is sultamicillin 25-50mg/kg/d orally in 2 divided dose depending on severity of the infection
Contraindication: individuals with a history of an allergic reaction to any of the penicillins
Undesirable effects: Sultamicillin is generally well tolerated. The majority of side effect observed were of mild or
moderate severity and were normally tolerated with continued treatment
Instruction for use/handling:The reconstituted oral suspension must be stored under refrigeration and discarded
after 14 days
Warning: do not use in patients hypersensitivity to this drug, this drug may cause hypersentivity reaction and may be
fatal, stop using the drug and consult a doctor if rash, irritation or edema occurs
LPD revision no. 1.2
Further information is available upon request
UNA pas 04 078
l1Jtl'tC}jl\llT~~rnlL\'l1J~ ~A.9;8/;550.
,j1'J~-:lf>l3J Vl3J'fl ID & ~3J1~n PIDST
.
f1mr:UUL6ltJ rJA.VmJ.'t1AUa
v
,
etd.
9J
d
QI
•
d
'Uru~'Vll'UCJ'WI9l'l-m 1J1J'W
Ufl.lltJav
a'lJU'iltU (aiiGlL11f)
tI
d
I
(12-16 :JJ'W lrUJ 2553) '1111 m~:JJ. :JJmlm~'Vl:JJ'YJ fl9HJCJ1~:JJlfl
.J.J
d ~ d 91'
ci
lIJ9J
fl1J fll 'J '\{:JJ'\..j:JJ'U El ~fl 'WlffEllll9l~ 'll' ~ '111 n 1 fldl ~ ~ m 'J 'il1J 1J 'W 'il ~ 1I~:JJ El ~ Ell'W 1'J 1flfl ~ 119l 'Vll~ El El fl
QI
I
QI
I
QI
.
~
~
~
,
fJ:JJ 1 'J lll~ 'Vl CJ II ~ ~ IVl V 'W 'ff 3J 1'li f1 'YJ f1 'I'll 'W
~I d ""
"
"
lU'W'Vll'JCJ1J'JElCJlWl
l'illu'J~l')ruWl'J
'1 I9lVlW!'Wl
" ~ '1-u'Ul~'I1'Wl
I"
"
El~11V'W19l1:JJ ~~ l~'YJf1El~l~l'i'v~m'W 'il1Jflf1J
liYCJ'\Ii
~l'WV1J'Jm~CJ~~'W "Update on Pediatric Infectious Diseases 2010" li'iV
~I
~ 'l 9 " .d
d'od.,
'UVlu'W f1l~~ 'ill 'I1ll~V'WllVl'Vl(J'Vl1 'J n~CJl1Jl1:l
1'W~
.
,~
" •1
m·il
10-12 fl:JJml~'W1j
2553
,
QI
'Vl~'I1:JJ19l
"'"
1Jl'Wl:JJV~'il~
tJtll'n\1l9l~h ~11'J:JJ'ffl'Jl:JJeJii
'I
,
~" "" ",)
'UV 9"
1'I1'il1Jfl'W19l1CJI9l11lEl~
420 'Vll'W 'I1'Wlll'W'Wl'11'W'YJfl
tJ
Q,I'
,
'I11nlfl~
9JQ,I
,
('lel L'll'~flUI9l)
9J
Q.I
19l'.i1Jfll1:JJ~fl~1J
iJN'l.ul~l:JJtJ'.i~'11:JJ
"
,
ll1J 119l:JJIVlCJ1J'W~fI~
ci
d
..
eJ.t]~1'1l ~na.JIf)1f1f1 (tJ 'J ~1i 1'W El'\..j m 'J:JJ fll '.iN flEl1J'J:JJll~~'ffEl1JEl'\..j m'U lfJ:JJl'J n'11
fl'l'ffI9l{hfl~I9lI~El ~l:JJn1J eJ.fiUtl1{ ~1iun~ (h~VWl1Jl1:l~V'l'lmmtU) eJ.~''.i 1.:jflll'1ll'~
0
.dt
~V'l'1"1
d
I
9J
I
11~~IVlV'W 'Vl'l1l 'J 'YJ f1'Vll'W 'Vl19l V~'lillJ
vllmrl~~l~'l
'l'Wl'I1\9lf1l'JtU1'Wl1lJflf.:ld
'W Vfl 'illfltl
Q.f
•
.::::l,d
'V
9Jd
~
o<:::l
'D..1J1J'W :JJ~1 'J CJ f1'J V.:l:JJl:JJl f1l '11~ V If1'W
('ffm'tJ'Wt11'JlfY'W'.il~'J) ll~~ U'V'l.1ll'ilW 1~t1a.J~~lIn'.i ('~l'wm~1JlI9l~'VllJl m~.'ff1i.) \1l9lfll'J
El1J 'J:JJ 'J ~1J 119l ~'Vl CJl'~h '11 f 1J IIVl'Vl6tJ 'J ~ ~l,j' 1'W ~ ElCJ ElI9l 'ffl'U 1fJ1Jl'J 11'lifl'l 'ff19l n'.i fI~ I9lI~El
~ 'W fI f~
¥iv
ll'JfllW~El'W fl:JJmi'WTI 2553 iJN'I'li'l~l:JJEl1J'J:JJ 15 Vll'W tll'i'fm\'l'11:JJll~~~I9l'l'il'illflN'l.ul~l:JJ
' "
"
'J~CJ~i'W~~l'W:JJl 'I11dl'il~\J f1 'l'il'YJf1'l fI'W
tw
tJ'J~'\i:JJll~1Jlfl'il~~ '1 'UvlM\1I9l~V'ltJBfl'W~fl~ 111:l~iJ'I~lj:JJV1JtJ'J~fllfYi1CJ'tJI9l'J 'l'W1'W~
MV~tJ'.i~'\{:JJfYHW!'Wlilfl~
,
fJ:JJmi'WTI 2553 ru
.
4'W 9
flV~fJ:JJlm'11m'.i:JJ
vlm'Ji'11'.iil~l'Jlm
,
9J
dl 9
d
do d.
~
~
~,
'JVl.Vl'J~:JJ~fJ~lflm 'll'~ l'Wl'Wll9llJlfl'W'W:JJfll'J1J'J'JCJ1CJVHfYfJl'JEl~ Hot
QI
QI
23
topics in Pediatric
Infectious Diseases in USA." LI9lCJ Prof. Phillip A. Brunell 'illfltJ'J~I'VlfY'ff'l1f~Vl:JJ~fll IW~
LH1~I9lI~v~'tJ~lmJ1'WtJ'.i~I'VlfY'1'VlCJ LI9lCJ
1
m:JJflJ1Jl'):JJ 'Jflm~'Vln~'ffl1il'.iru,,!'U
'V'lty.1'.itll
l'I1~3.:l~eJU
d do 9Jc.
l
d"
fJ:JJl'.ilIVl'VlCJI9l119l'W'UV~'VlluIVI'll'CJ
tid
,
d
...
~ll'tIlf1'.i
(Outstanding Asian
dl
v.v.I:JJ-Wirurul'll
~
..s
'W ll'Jfl"1
~ljl'llrV~
What's new in Reclbook 2009 'l'W~l'WV1J'J:JJ
111:l~'Uml'W~'I11flV~:JJ'\.rlmJ "mUI1'11" 1:lV~
19l1:JJ ~ V 1tJ IrVCJ'l
91.. . '1
c:;;
111 'W tJ 'J ~ LCJ'11tl ~ V vi 1'W
<v
lV~ll~~~UltJll'l flm 1J
'"
1J'J'Jrul1if1l'.i
'illfl-fflUfl hfl~l9l~v~'tJ~lmJ
Q,I
fl:JJ~19l19l19l1m1J'\i ~flflflfll'l1:JJV'WlI9l:JJ
'IllltlVl'il:JJl'lfl'l1'11VCJlI~I'i'V~'UV'UCJ1CJml:JJ¥lVll eJ.eJ'lll
q
H
W dl
QI
1.'I'~tJ'illfl
l'J~i'lJ "1W!'W1'.i 11'l'11
.
'UV~l'Jl 'Mf1J'Jl~1~
Award 2009)
tI
.J
Pediatrician
c:;;
Q
'illfl Prof. Sanath P. Lamabadusuriya 'll'~ltJ'W President 'UV~'ff:JJlfl:JJfJ'lJnllVl'VlCJmflVl'WWI'll'CJ
IltJc]H'~fI
ru
'1111 fJ1Jl'J
'Wml~l'J~tler tJ'J~I'VlfYm1il'Jruf~tJ'J~'11l'11'W~'WI~eJ1'W~
Nlf11JVf111
d
.:::to
I
c:;t
........ 3. f1t]'llWl !'V'l.:lll'l
mfl~'11lfJ:JJl'J n'11fl'l'ff19l { flru~n'11fl'l'ff~l {1'Ul9lfV'W :JJ .:JJ'I1I9l~ lJ\?\'1Il'l1'11~Vl'ill'J611~
v~lm'ff'W 'l'il~I'l~ElI1JV{
'JVl.~V'l'l"1
14 \9lmmJ 2552 lnfll'Jl
Ql9
9J
II Vl 'Vl CJ'U V 'J 1:JJ II 'ff19l ~ fIJ 1:JJ l'J'W I9lIW ~ iJ:JJ I 'ill'lll'J'W~fI~
oJ
02-3549161
"0
~.I".d
l'Ul'Vll~l'W IUII~ll:JJV
tJ~II'i:i'liJ
mfl~lfl:JJ
~~'il1J
3.1'.i1'.i'.iW 'l1l?llltT.:l'l1
Fellow ID 'illf1
..
_1.1
~ ~ d'
:JJ'UllVllf1u'J~'lil'ff:JJl~'W1i:
"'"
2552
QJ
Chapter of International Society of Tropical Pediatrics (TCISTP)
Q.I
dl
,
-=t
~
'"
~
U~~'Wfld'ilCJ
""
"d
9
•1
'Jl:JJ1I~~'Vl1.'l''W 1'il'illf1u'J~I'VlfY
'j)
'il1'l19l~'UWl~Vfll'J'ff'Jl~
lfl~ V'IllCJ'J~'I111~fJ:JJ1'J II Vl'Vl6~ 'ff'W 'l'iJ hfll'U\>ifV'W 'l'WI~ f1 LI'lCJ~~'I11~ 'lMfJ:JJl'J 1ll~'Vl6
'VlNfll'JIIVl'VlCJd'
Thailand
'1 'VlCJll~~u'J~l'V1fYI9l1~
_1
'
'1
Society of Tropical Pediatrics (ISTP)
1.'I':JJl~f1 '1I'i'~ -fflUf1~1'W
.;, .,
'Vll11:lf1
'1 1'l:JJ
"""
iJ f1l'J Vll~l'W ~ 1:JJ n1J The International
1~'W'I1'111l'J~1'W'lm~~1Jll:U'IllCJ 1.'I''Wl'il1.'l'iJfl'Jl~'W
TCISTP mfl1'lil fJ:JJl'J l1'lifY11.'l'19l {1'U 191 f V'W
flru~n'11fY11.'l'19l {1'U 191 f El'W
:JJ.:JJ'I1I9l~ 4205 1I'W'W'Jl'111~ l'UI9l'Jl'11l'V11 f1~~I'Vll~"1 10400 LmrrVlvl/L'Vl'J'ffl'J 02-3543269
www.tropped.org
" ,.,
l'Ul1:lf1'l
9 ""
.'1
l'I1'VlV~ueJ~
,,!1'l'l1'lCJ~I:UCJ'W'UVNlf11'I1'Nf1f1l'J'I1ll'J 1'il1~V 'l MiJ,,!'UmVl~ LI'll'J 'lM'I11l'J 'l'il
•
~
""
,,~
9 ~,,~
""
(deep diaphragmatic breathing) 'W1J 1
20 ll'i:i'1'111CJ1'ilVVf1U1J I
D~
10 vll 10
flf~ "1'W~~
11~
3 nm
5
ll~lf1~'W'I1llJ
"1'\.JVl'i.UJ~n~ t:;i'lfb~'lIl
~"1'W'Vl'WVl.~'I1ru, ~'W{1"l1ru
,
~
1.Jflmm
11 '\Ii f1l'J 'I11lff'W V VI ~ ~1'W 'I'll ~I'i' 1'W ~'lil f11 'J 'J l:JJD ~ f11 'J V iltJ 'J ll'JIW fll tJ~CJ'W fll1:JJ f'Vll~ 1'111 f11 'J ~
I~CJ1.uV~ n1J hfll'Ul9lfv'W 'l 'W1~f1V~NiJtJ'J~iY'Vl!iim~
~mm~n
l'illl 'W1J 1
11~
f1J'JV~1~1'W'il~firf1l1'i'lliJfll1:JJ
f1'.i~~:JJf1'J~'11ll'J'ilj~'l ~V~vll~'W~fI~
'ff:JJl~flvil'W'll'liJ'li'tl~I'lI,:f'WV~l~ 'h'l1rvl'i'v~f1lnr~'Illl:JJl~~~~fI:JJ'I1:JJV ID 1~f1 f1~ ru 1
""
"
~ 9
"
email:[email protected]:l1Vl1Jf1.WI.l1:JJfI~
"1Vlb1J~~nb1Jb1Jl t'l!i'l1Vl\!~tJn"l
tJ';l';ln.nfim';l
~"1Vl'fl'\.J~.~~:;itJr)~'\.J~db(i)'l!
';l'el..:ltJ';l';ln.nfim';l
~b1J'l,r'Vlllim Vl'l';~l~l~n
fl'el..:ltJ';l';ll.'Ulfim';l
~b1JJ..:l~~l t:;i'lfb~'lIl
Vlb1Jtlmmru 1J'l~fh~'lI"l~
Vlb1J~h 'l'l~~r)~~
e.J"1~ru'l1"1tM~'lIU~lru
,
~
>­
~"1~b1J05"l'll~1 i#I'l~mVl~~'l';
'W~'Vl~'l~~ i#I'Wl?l~l~'lD~
'\.JVlVldb'VlVl
~l,rn,:n'U"l~'i'll'i"1 Vlll'ltJhi'l~"H~'1l n'1l.:J~mm'llmnJ '1l1I'l1r~'llrn~mm rVlVlr~~.:J~!Jbn~l
b'VIr. 0-26448971 b'VI'ri'm 0-26444135
~'l'\.J(i)'iln
~b1J oW~VMruru(i)l L9tJ~~~
REVIEW ARTICLE ~f),r3JUUtl~U't1~113JT(;ltl 'Wty.-W3J.w.wWW(;ll b~mf~tl (T';j\l'WtllUltlA~';jl"lj)
What's New in Redbook 2009
~.:J<D~~~~hW American Academy of
<DWJll~'W'I1'U.:J fliJ~l.:J 0.:J~rllr1'Ullci~'I1~ ~ hrNfm
'I1'U.:JfliJ Redbook
Pediatrics (AAP)
~
, ~
1 c;
"i
>lei
"i
1 c;
1)f1\9l~I'liiJ 'Wl~fH)(J'lJl)(J~ 1~(Jl';jl'li(J1'lilty 1)f1\9l~I'liiJ 'WI~il
"i
Q
eI
'"
eI
Q
0
'"
ill'l1'W~
~~~l), 'lJ'IJ 1'I1~I~iJ 1M~'W ~ iJill) ltJ~(J'WlltJ~.:J~ln~~'Wb 1~ ill) II1~'VI6'V1 il'l
l),'lJ'lJl'11~cil'11'~'lvi'mil),'lJ'lJu f1.fl'. 2009 'IJ'VIml~rivi'I~(J'W1l~'UiJ~)tJ
lifiJ'I1l~ltJ~(J'Wll~~.:Jrllr1'ty'l l'W'I1'U.:JfliJ Redbook l),~'lJU f1.fl'. 20;9
3U
~iJilmtJ~(J'WlltJ~~ 1 tJ1l1ilmJ'lJtliJ'W'I1Ulri~~l~~~1 'WU
-
'lJflfI~~'W'l 'VIf)f1'W~lJml~I~(J.:J~aill)ln~ ()f1 meningococ­
1:~~1vi'1'IJl~91'WlJlll~1 1 l~~ ll'W~tJllMU~lfl91'WJl 5 U
cal disease
Q.J
Q
d
Q.I
'11 ~ ~'iJ 1f1lfl 'li'WI'Uml) f)
tJ) ~ I'VI fl"l 'VI (J
• v
cJ.:J iJ '1 vi'lJrll II 'W~ tJll 'W f) U
1Mlfl91'W U~~ 1'W
'lJflfI~tt 11 tJ'I1~a'lJflfI~f)ci~I~(J~ I~a.:J'iJlf)'11'l(J~'W ,j'Ua.:J14a~~'lJlJlf)
q
q
",'l
q
1 'WtJ)~ll~fl'1 'VI (J'U'Wfla'11'l(J'Vr'W ~ B
~.:JiJ'lvi'a~l 'Wlfl91'W,r'WIa~
fl. fl'. 2006
Community-Associated Methicilllin Resistance Staphylococcus
Inactivated Japanese encephalitis vaccine (JEV): lllJll lEV 1l~
I~ 'W 1f191'W ~ II ~ 'VI 61'W,j'1'W I) l~'WIfI (Jl ~ iJ ~ ill fH) 1iJlf191'W 1'JflJ 11 ~ 'WI1m
•
•
~l
'j}
methicillin, oxacillin llJ'W\9l'W
QI
(J~f1.:J
lil
l:1>1'
~
'iJ~~a\9la(Jl~'W~l'W ~llf)
td
I
v
~,
d
aureus (CA-MRSA): l'lia CA-MRSA
~
I
n\9la(Jla'W'l 1'li'W clindamycin 'I1)a
v
'I ~~a\9la(Jl
,'" ,
'Wl'Wll~l 1l~I~iJ~1l1ill'WtJ)~I'VIfl''11''I11~m~~illm'l!I~'W~'W)~'IJl~'UiJ.:J
()f1
~I
>I
trimetroprim-sulfamethoxazole (TMP/SMX) llJ'W\9l'W
lfl91'W~.:Jl~'1vi'iJH(~(Jll~1'11m(J 'I1'U~fliJ Redbook l),'lJ'IJ fifl'. 2009
d' ~
cv
d.-::::t
~
«:S
tlB'lh'W~'I1m(J'liU~~l.:J'iJlf) MRSA ~lml'Wh.:J~(Jl'lJl~ CA-MRSA
1~'WllUl'l1lrllr1'UI~~'lJmf)1'WtJ )~11~fl''11''I11~iJ!~~ f)l 1'WtJ)~I'VIfl"1 'VI (JcJ.:J
ci
I
0
0
'WlD'W l), 'IJ'IJl!) il'VI~ ill) f)m1m lEV ) l~jN~mll 'W~'Wl1l1f) Advisory
c: w
9 >I
Committee on Immunization Practices (ACIP) lil(J1il'IJill) I'll lEV
Bilvi'l(J
iI
,
(~(Jl~'Wf1111'W~tJll'Will)IM
lln'IJflfi~~iJm(J~~II~ 1 U
lEV
<l
1
q
~'W 1tJvHJw·J'W ill)1l~I~'W'VI1.:J 1 tJcJ~~'Wll~'WvHJill) )~'IJl~'UiJ~ ()fi (~(J
o 9 ~.::i
11'W~'W11'l1l),~
c:j.=:\
Q.J
.d
3 l'UlJ'VI1'W'VI 0, 7
lW~
30
9 '3J ~
'3J
t
'3J
lW~ 1'I11'U~~~'VI1(JiJ(JN'WiJ(J
10 l'W tliJ'WiJiJfH~'W'VI1~I~iJ 1MmJ1 1l1111~ill(J Llvi''11'fl~f1iJr1lJfl'W
'1vi'I~lJ~
ll~ ~ Il1iJl ~'W ill) ff ~lil\9l iJ lill).,j'l.:Jl~ (J ~~ iJ 11l1n ~~'W 1l~1 il~l) 1Mlfi91'W
11'W~tJ 11M1'IJlfi91'W tliJ'W ill) 1~'W'VI 1.:Jlll, ~l~'l.Jfifi~~m~ll1l~ 1'Jf
!lmiJ~l.:JUiJ(J I l~iJ'WiJ~I'W~'Wll~'W)~'IJl~ 'I1~iJ'l.Jflfi~~m~ll1l~l'Jf
Bf)vi'l(J
'9 ~
'3J
I
nmiJ~ b'W~'Wll~'W)~'IJl~'WiJ(Jil~l
1
~
l.-::::t
0
~I
'3J
l~iJ'Wll\9llJmllJ~lllJ'W\9liJ.:J
g
'3J
l'linm
u
u
lW~
~
'1~~'IJ!!l~1'11m(JiJ) l(J.:Jl'W~lh(Jl~f)ua(J fIl~lll'W a'W lfl\9l CA-MRSA
m'iJl~'WllUl'l1l,hr1'UI'Ua~tJ)~!'VJfl"l'VI(Jm(J~'W,j~~'lJLia(Jlvi'lltl
u
ll~~
USA300
ll1l~(Jl~(J.:J~af)l)~~I~a'lvi'll~f)l)mft(Ja~n~rl'Wa~l~
USA 400
'"
llm)~ f)l)H'Ua~1'Jf,h'W1'l111~n'W hflN1'l1'U~eJf1!'11''lJl~a1~ hflei'l'W
ll~~ lfl'Hj~l'W~~"l~~
ll1l1l'lJ'Wl'W'I1m(J 'l
'I11J1(J.:Jl'W'Ua~tl)~I'VIfl'
~al~~ ~lCA-MRSA f)~~m~'WI~atla hfl~ rllr1'Ulll~~lmLia(Jf)ll
'11''111~
~
Hospital-Associated MRSA l'Wf)l)na lMln~f)l)~~I~a1'W () ~~(Jl'lJl~
f)l)~~14a~iJ'11'l!'l1\9lm'iJlf)
~
q
umva ei a'W
1
q;
(~(J~ 'lJmf)~ ~
'11'1'W lJl il iJ (J'W iJ il Dlfil) '11'til'W 'VI '11) iJ a (Jll ti 'IJ'li'W 'IJ'VI 'VI a 11l ~ f) 1)) ~ 'IJl~
fa(J~~
'UiJ~ ()fUJlil
lvi'Lia(JeHVll'l!'W folliculitis. abscess lW~ cellulitis 1~'WI'i''W 1'W
I
r.:::t
,
"":i
.::i
I
~
d
~
85-95
.
'Ua.:Jf)l)~~I~a
l'Wvi'lh(Jl~m:f'W
CA-MRSA
'JI
ri1'Wm f) 'j)~l ~ 'W f)l) ~ ~l~a 'U a ~N I'll 'U.:JlW~1
.
.<::l..t!.
QI
I
QI
'lJl.:JfI).:J f)l) \9l~I'liD~ ~ f) ~llal'iJ
Meningococcal Disease: lh~'lJ'Wlfl91'W{ja.:Jrl'W hfl meningococcal
disease
'3J
.e.
~iJ1l1'l1th(Jl'W tJ)~I1~fl''11''I11~mlJ~illl~'W
1Jj 11
Q.I
'li'W~~l(Jil'W
Qudsivalent iJ 2
I
!~llil
Unconjugated ACYW-135 polysacharide
ll~~
IifmteJ 'l'111 M1JG1'
,:f.:J'I1JJ~l'W~lhm~f) ~~'IJ
CA-MRSA
d
~
r
d
alf) 1) )'Wll).:J
f)l)! 'W 1\9l1(J'U a.:J
~
mjT,).j~f1~ltJfI~.:J rl'IJ f)l) .J'ti f):l~ .:J~~'liU
~,iJ~1J rl~ G1'f)1J W~
'
~1fl'1Jfla lJmmlJf)l) !!'V~1 m~'iJl(J'Ua.:Jl~a"1tJcJ.:J'lJflfI~~'W'l 1'W,j'1'W lW~
.?I
l.r] g)
d
d
Ll >I ,
.
3J
'iJ
'j}
0
Q.I
q,
,
d
.:::::'I
ACYW-135 conjugated vaccine (MCV4) rll'l11'IJ MCV4 'U'W license
~'lJf)~'lJllJ'W'lill~'11'.:J)a(J~~ 10 ill)\9l~I'liall'IJ'lJa'W'l 1~~'IJ ~1'li'W
~
~
d
9
9J
0
Lrj'JJ
I
\9l~I'lia'IJ)!1W 1'IJ'I1'WllW~mfla
I~llf) cervical lymphadenitis,
Ml'JfMrll'l11'IJ'l.JflfI~al~ 2-55U AAP rl'IJ ACIP 11'W~tJ1M~~lln
toiditis, sinusitis, retropharyngeal abscess, periorbital abscess llJ'W\9l'W
v
Q
f)l)
mas­
~I
v
v
,
>I
l(J1'Wl~ilfi'W~iJtJl(J)~'I111.:J 11-18U lW~I~f)'VIf)fi'W~iJal(J)~'}-dl.:J 'IJl.:Jm ~al'iJYI'IJf)l)\9l~I'lia'VI)'Wll) ~mf) (invasive infection) h~llf)f)l)
2-10 U ~iJml~I~(J~'11'.:J~aill)!n~ hfi meningococcal disease 'liU~
~ ~1~a'Ua.:J m ~~ f)IW~eU'a eJi.:JlJf)~'lJl~'W 'I1m(J1'1111 'I11J~ l~l~!~a~'W
a.
QI
q
q
q
q
~
q
'3Jdci
.:::t
r
' J I ,
l1J '3J
,jldd
.:::::..<tt
1';j'VI~f111~1'11'(J.:J\!.:J\9laill)\9l~I'lia
!~1lf)1';j'VI~fIl1~
,
3J
::II
~
'"
~I
'9
eI
'iJlf)ma~llJ'Wa~1'W)~(J~!lm'Wl'W m'iJ!f1~~
persistent
- 'lJflfI~vi'~
1NllN'W 1l~1~'W1~1.:J 'I tJ '11~ a 1l~ '1 tJmft(Ja~1 'W ~'W
,
11~'W~iJill))~'IJl~lJlil'Ua~ hfi 1'l!'Wvi'~ 1l~1~'W'VI1~'I tJtJ)~ila'IJ~lji 1l ~
~
venous thrombophleblitls
"Ivi' leU'(Jll'Wl'W vi'a.:J~f)1flml'lla~1'W h ~~(Jl'lJl~I~'W)~(J~!1m'Wl'W
•
~
v
..:::.. ~I
.:;\
d
.<:::>,
r.!!
QJ
l:l 'j}
!w~m'iJ!f)~llJ'W f)l)\9l~!'lia'li'W~I)a.:J).:J ~
'" asplenia
complement deficiency 'I1)a
~
'j}
q,
Q
"
-
lr]
Q
'JI
~
)'WI!).:JMlltl
q
d
9J
QI
Ci
'Ua)~l~f1D
v
d
myositis 'I1)a
pyomyositis Lia(Jfl1.:J1l~lm11~rl'IJ osteomyelitis
f)l) iU'iJ U(J ( ) fI ~~ rll r1'UI fl a 1l~vi' a.:J~ (Jl (J1JJ ri.:J f)l) I~ l~ 14a
vi'~~l~a Human Immun~deficiency Virus (HIV)
lW~\9l) 11lfl11~'11~a(JltJa1h'W~;If)l'1111 'I11J.:J~lJf)n~~14ml~~'iJlf)
'Wail1l1m:f~ ACIP cJ~ll'W~1..hlMlfl91'W MCV4 Jll~am~vi''W l~a~ (~(Jm ~l~a~l~t~ ~ ~ri ~\9l) 1'iJ~ lvi'm'iJlf)f)lH~l\91~)~'IJl(J'I1'Wa~
iJiJ~~n'Wlltl'l.JflfI~I'l.:J~al tJri
'
'I1~am)1'11 debridement f)l)H imaging study 1'l!'W ill)l{l MRI iJ
-
!~il~'1vi'1'IJlfl91'WI~iJll)il~al~ 2-6 U ll~~cJ.:JfI.:JiJml~
1~(J~'11'~~ailmn~ hfl meningococcal disease a~ (~(Jll'W~tJllM~~
-
Jl 3
~U ml~'iJlillfi91'WI~~ll)il
ri1'W'I!1(Ja~1.:Jmf) 1'W f)l) iU'iJu(J hfl ~1J1(Jvi'a.:JM1'IJ f)l)\9l)l'iJtJ)~liJ'W
t
'lJa(J'l
ml'l1~
I
d o ,
=
11
Ci
"
dd
l~a'l1l\9l111'l1'W~ f)l)\9l~I'lia'VI
d
I
d
r
9J
d
d
,
Co
"
,&
a'W'l 'VI Dl'iJm1~~1(J'I1)a'VIIf)WU'W
Redbook I~Ud' {l'~LJll'W1'Vll~m~~1l'J~1J1CJ~~I~{)CA-MRSA
tl 11u'W
'" ~I flow chart CJ1U{j'lJ'1'W:;;'Vlll'W:;;'Wl
_I "'.,.
""
0 1
.,."" "'_'I .,.
'Wmru'1~u1CJJJ{)lm~~'Wm~
fl{)
vancomycin ~lJJf)'lJCJl nafcillin ('l1~{)l'WLJ~:;;l'Vlrr'I'Vll'J {)l1Jl'lf' clox­
acillin)
~~;il~{)l,rm{)'lJfl~JJ~~ MRSA
'"
I'"'l1
{)l1J"~1Jl~rul
S. aureus (MSSA)
lW:;; Methicillin susceptible
gentamicin
~
'l1~{)
,
~lJJ
rifampin
eU'{)JJ'Jl~CJ1f)'lJLJ~:;;ir'Vl ~i1l,,~'U{)~nU '1 ,rCJ1{l'{)~1'11'l1~~;i~ 1JJf)'lJCJl
LJB'lh'W:;;~~
niJ~iJ {)cil!{)CJ vch'l1f'lJ
m ~ ~ ~l ~{)~ "hh 'Wll ~ ~JJ1mr f1l'lf'W
v
,
t11JllCJ~iJml~{)nmf1~ neonatal
~
~
~
q
.e:t
QI
<:!:i
I
m~\il~I'lJ'{)'U{)~N1'l1'W~II'J:;;I'W{)W{){){)'W
CJl clindamycin
1~'WCJ1~iJLJ~:;;iY'Vl ~ .fll,,~~l 'W nu f mil
m
<:!:i
'l1~{)
TMP/SMX
dd
'
- m~\il~I'lJ'V'UV~m~~l'VlI1J'W primary infection l~CJ'VlunYi
,
,
fl~V~1Jlnm~~lYiiJ primary HSV infection iJmlJJl~CJ~~Vmdlf1~
,
v
~
~,
I'lJ'Vll'lJ'lJ reactivation
i:I~
10 l'Vll
1'lf'Wl'Umill~m~~llfl(JiJm~~~
- Transplacental antibody
l~vmtiv'U
'"
~ ~ 1JJ f)'lJ m~ I~11:;; ~ :;;'lJlCJ'l1'W{) ~
-
m~
"
9 9J
~.<:::\
iJ~ 'b.1iJr1111'W:;;111~~'WiJ'W
N'Jm~~{)~f)'W{)cil~i'~I1J'W eU'vLJB,j'~~Vl1JHirXl'lf'W m~~II'Jf mn
~'U~nElru:;;~~ 'l1~f1l~CJ~nUll'lfJll'WeJl~{)lmfl BHJJmJ{)CJ"l 1'1~1~'lJ
'1 ,ri'WV~I{l'JJV fl1~'l1~ f1l~CJ~ f11J m nJ~ {)11J'Vll 1,rlf1~'lJl~llN 'J'lJ'Wr:h'l1'l!~
'l11niJ'lJl~llNmf1~~'W m~1J~'lJl~llNmi'W '11 'l1~f1l~CJ~nu Hlflr{)~ H
ftl'W\?llj l1Jn'W l1~'W ~1~vllf111lJ'ff~f)1~~'WN1~()1l\JiJ'Wl~V'l-a~f) eJ1Yl
CA-MRSA
1'lf'W 'U{)~I~'W 1l'J:;; ~LJnnu~l~
- Mode of delivery
~
~
CJ~'UrJ n1J:;;v~n~JJ
caesarian section
eU'vVJ~i(~lf1\il~'U"l tMllti LJ~d'~JJ1~~1IflCJiJm~~~I~V HSV
,
'1
odd
mnv'U'W'lJ JJJJ1n m~rrnEll'W'lJ11~VCJ'J:;; 60-80 'UV~'11~n'VlW)11:;;
o<:!i
t
,
9J
md~liJn1J:;;'hJiJLJdd'~Vlm~'UV~m~~~I~V
neonatal HSV infection
1l~:;;m~~1~MLJ~:;;i~111flviJvlm~'UV~genital
d,
do
HSV mtiv'U
9J
Q
neonatal HSV infection 'UVV
I
d.:.
Q,J
,~o'
mlm~~l'Vlln~m~\il~I'lJ'V HSV ~:;;'l111~\il~m~.fl
eU'{)m~LJB1J~rll'l1f'lJ111~n~fl~V~1Jlnm~~1~iJactive genital
'IrXlltim~,fl HSV culture ~Vl~ 12-24 41 lJJ~ (1Jln
3 1l'lJ'lJrX1CJf)'W 'lrXwl
pneumonia, disseminated intravascular coagulation
c:
~
m~fl'Jv~LJn~iJmlJJl~CJ~~~nl1m~,fl
'Vll~n'Vllf1~m1J:;;JJfl11JJl'CYV~\il{)m~lf1~
ll1J~nu~~I~V 'lrXl~'W
<:!:i
""
d~
1. Disseminated disease 'V~'lJ'lrXLJ~:;;mrufvCJ'J:;; 25 Vlm~
v
.:::::,
mlJJl{l'V~
HSV
Neonatal Herpes simplex virus (HSV) infection: neonatal HSV
I
1"~JJfl11JJwrJ~\ilVm~\il~I'lJ'V
1'lJ' fetal scalp monitoring
- Duration of rupture of membrane
m~~{)~f)'W m~~~l~{)
~"~'lJtJ{)CJirXllti
mlJJl~v~'Uv~nU~~I~vl'U
(hi'l'lf primary infection)
'Vll~nn1J:;;'J~'J~
~lCJ~~1J:;;'MN'J~
infection
,
neonatal HSV infection JJlnf1'"ll'Vll~nYiflM~1JlnJJ1~~lV1iJm~~~
rX1CJ
<::lo.d
HSV infection irXllti
.J
HSV lesions
I~JJ1,r,fl~V1V
9J
c:::
411JJ~) ,f~;il~vl,r'11~n~iJvlm~LJn~'lrX
24-48
J<i
dd
~
c:::
d
(DIC), hepatitis ll'J:;;'W'lJiJ Central nervous system (CNS) involve­
fW'lJ'lJl'Ul~1'U'U l'Umru'1m~~lJJ{)lm~'Uv~ genital HSV 11J'Um~!l~n
ment M()~f{)CJ'J:;; 60-75
~1'lJ'V1'lJ'lty'lJl~'11'Ull'U:;;'U
QI
9J
2. Encephalitis (CNS disease)
QI
'W'lJLJ~:;;JJ1rufvCJ'J:;; 30 ~1J1CJ
QI.r=2
'j.I
JJnJJ1~1CJ{)lm~'lJ'n
'liJJ irritability, poor feeding, temperature
instability
"~'lJ
3. Skin, eyes and mouth disease (SEM disease)
9J
~
.:::.
d
m~liJ1J,rCJ neonatal HSV infection mHld1\Jfl'Wl'WJJl\ilJJ'Vl
rJJJ'Yl1 i~jJti
H swab l-WCJ~
I~VV11J"~1Jl~ru1
{l':;;VlI'l tl LJV~~lll'l1U~l1'WlrlV'Wl~V
(culture)
1Jln~lll'l1'l.i~
1Jln~JJJll{l'
~~ci~\il~1'il~1f1l~{)~
(t1{l'{1'l1:;;
ll~:;; ~'il'ill~:;;~nl'1~{)vn
'ILJ
'illm lCJm~ir~ci ~\il~l1JYim~ci~)
ci~Jl'1'Ucr'W'l1~~m1'il
I
CSl:1'"
QI
V11{l'JJV)
~'Vll
'l1 acyclovir llf111Un'l1M1Jln'Vl
acyclovir, mCJ
culture
9 "1"
'"1'"
"'''''
~'1'JJll'U:;;'U1!'l1
~n\illJJ~I'lJ'V1'lJ'ltyJJfl
'l1Vl
VV1~
0
.,.
'lV1~
acyclovir lIn,
HSV ('b.1l'lf primary
, "', 1
d
c:::
infection) mn{)'UllJJ11 'W'Uru:;;'Vlfl'JV~1J:;;JJ active lesions n\illJJ
0<:;1
,
I
thjl'lfm~~~I~vflf~llJf1l{l'JJ{)
tlLJ
d.:;"
4
v
v
rI
ll'l'I11V
Cl.I
genital HSV mn!pl'IJ').Jf)'j·:mm lJ7y
~
1'W m ill'UV ~'Vll~ n~fl 'JV~ 1J lnJJ l~ ~l~iJLJ~:;;i~ 11Ifl(Jl~'U geni­
tal HSV mtiv'U ll~l'W'Uru:;;Yi1Jlfl~v~thJiJ active lesion ll'U:;;1111,r
iJ~ln\9lV1f1lJ'U{)~'Vl1'H1 ll'l~ tl~mJ1f1f1lJ l'Wl~14eJ~Vl~ 12-24 i'1 hJ~
~
" acyclovir 11'W'lVm~
'" 1"'0
lW:;; '1'
JJfl1~ I'"
'l1m~~nEllll'lJ'lJ
empiric mv
'l1m
II 'U:;;111 f)'lJ LJ nfl ~ V ~1~V 1f)'lJ V 1nl ~ 1l'J:;;V1f1l~II {l'~ ~'U e:J ~fll 1:;; neonatal
vr
~
..A 9 ~ ~'" I
c1
rI -d d
n~v 1'l1~unmV~~'lJ'Wl'11~m.l1'W'lJll'W'VlVlW)JJV1m~
r:l~LJn~1~vl1nn:;;vci1~t~1'U'lf1~6 crLJ~lrfmn'Uv~9ii\il
l'Umill~N'Jf1lmn:;;I~V~Vl~
- DFA staining of vesicle scraping
- PCR 1Jlnl~{)~ e:Jl'iliJci1'W'lf1CJ1'Wm~liJ1J,rCJ l~CJe:Jl'ilci~
0
411JJ~I~CJ'lJfvCJllB1 'l1~VV11J.yj1Jl~ru11~JJCJ1'l1'UV1'l1~~fl~V~
l~v~tb.1~{)M()~ 12-24 41 lJJ~ (iJ~fl~II'U:;;1111,r1f1 culture tiV'Ul~JJ
HSV infection
HSV PCR (with or without culture)
'.V
~1V
12-24
1 ~'W lm:;;ci~ l~CJlci
viral transport media l-WCJ~ I 'l1'J{)~ l~CJrX{)~ swab
-
'1 9J
11'l1 empiric treatment,
f)dJ~)J;:'I1l.mm'JJrn7lJ7mJ'lJtN
conjunctivae 1m:;; rectum l~CJfI'lmd(1
-
0
1'j.1
.,
Cl.I
- Surface culture l~CJm~ swab 1Jln mouth, nasopharynx,
l"~l:;;l~{)
'1
I
'Vll~n~If1~1Jlnm~~1~iJLJ~:;;i~11IflVl~'Ugenital
LJ~:;;mruf{)CJ~:;; 45
-
d
12-24 41 lJJ~n~'lJ1Jll~'Umn
'Vll~nm~'Mf'lJm~\iln1JLJ~:;;liJ'Uvcil~'J:;;IVV~ ~lJJ()~fm1fl lumbar
" '1 JJJJ'JnElru:;;
'''' ~
puncture lw:;;num11J alanine aminotransferase (ALT) m
'Uv~
'j)
neonatal
.:;\
HSV infection
d
Cl.I
'J}
m'Vll~nJJ'JnElru:;;'VlI'Ul
Q.I
'Ul'U 14-21 1'U
0
1,;1
"'~
~n'lJ
I
o
9 "
ll'U:;;'Ull'l1 acyclovir
neonatal HSV infection
.e.
v,
~
d.c:.
d
v
\il1JJ\illll'l1'U~'Uv~m~\il~I'lJ'V'Vllf1~'U'U
~
'Ul'U 14 1'W
1''l1"
acyclovir
.
Q.I~
d9Jc!1
o
.
.
~91Q.1dl'
rm.w'ilmm hf'en acyclovir 111.w'ill'jru 11111'WmW~Cl thHl
fllll 'Wg;'Wl'li~11l'W I~ 'j 19;:IJ'U Cl"~ ~'j g; 1 ~fleJ fll'j 'Vl i;]:lJf):IJ fI'W 'Vl 'ff ~ N1'W 'il 1fl
'VllJfl~~ skin vesicles ~Cllfll'jifl~'Wll';i~ ~'jg;~tJ ALT 'Q'lmfl~~
tlfl~ ~Cllfll'j sepsis-like '~lJfI~mJ:HJmfl~~tlfl~ 'l1!Cl I'WmW~fIl'j
:IJl'j~lm'il '1 tl'jtJm'Wfll'j'fffl'li;]li~'lJtl'W~eJ pertussis I 'W'Vll'jfl'l1~~i'tJ1flq)'W
.
o
\?I'j'J'il'Wl
tl
if
Q.I
Q.I
.
'"
~l
I
mononuclear IlJ'W'l1(;lfl ( 'Wmru'W
a,
d
Q.I
'U'ff'W'l1(;l'lV~tJI9Hj(;l'li'W~
d
..
d
Treatment of Candidiasis: nfll'j tli'tJltl~V'Wf111l'Wg;tJl~~V'JtltJfll'ji'flEil
,
I"
'ff~tll~VcJeJ ~ltl~V'Wlltl~~ii~~d
Cll'il~Cl'liU'il.Q(JlWfll 'jfl'illfl enteroviral infection 1'i'1tJ)
candidiasis
Recommendation for use of PalivizumabT\J for RSV prophylaxis:
Mucous membrane and skin infection 'ffl:IJ1'jt1 I~ voriconazole IWg;
fIl'j Itl ~tJ'Wlltl (;l ~'l1 ~fl'l
~ n'U Cl 'I rll11'Wg;tJlti Cl n fllJ tl i'tJ Itl~ tJ'W 'U Cl 'l'lh ~
mn~.w'il 1'j ru 11~:IJ 111tJ 1I 'W ll~fIl~ 'j g;tJl~ I ~ tJ 'ilg;1l1'1 fl~ 1'1 tl'W 'I tl1'11:IJ
.
ll~(;lg;,r
Cl'l~'l 'W tl 'j g;1'VlfW'l1i'!
,
'"
I'WCl'l'illflVl
I 'W ~d 'ilg; h;'UClfl~l'J I 'W 'j ltJ~g;IVtJ~
v
'd
_I
tl 'VlV ~'ff'W 'il
'W'W ~1:IJ:IJ
'li 'WlJ'jg;I'Vlfl'
. .
T\l
Pallvlzumab'
'fflmHl'l11'jlV~g;IVtJ~I~:IJl~:lJtMI'W
l "I
"I
v
varicella vaccine 1'U:IJ'Vl 2
~1l'Wg;tJll11
ACIP
~ J' A
.,d
d
'Vl~'WI'WCl'lm'illflfll'j'~~tJ:IJ
d
breakthrough
infection fllV'l1~~fIl'j '11'i'i'tJ1flq)'WI-¥;V'l I 1~:IJ I~V,.~tJmfli:l~fCltJ(;lg;
~Cl1] 'l1!Cltl'jg;mrufCltJ~g; 7.3 ~Cl
0.2-2.3
v
d
Q.I
do
through infection 'lJfI:lJCllfll'j
3J
I
3J
:IJ~'Wll'j'l
,
'11
l~v,t'Jtltl
10 1]
~ "d
tl '
break-
,
0
Cllfll'j 1'U'Vl'Q'lflJl 39 C
3.1
I
~"
l~
~,
I
'WClVflJl'jClV(;lg; 10 :lJfl:IJI9J:lJ1'11:IJ1'1'J'WClVflJl 50 19J:IJ llml breakthrough
.
'" '1-
d
infection 'ilg;:lJCllfll'j
~
1:IJ~'WII'j~
,
"~
,oj
,
ll\?lfl'ff'jl'llJ11]'l1l
I '
'"
I'liCl lJ'Q1Jflfl(;lCl'W
(breakthrough. infection
I 'l'W 3
tl'jg;mru
~ "
~,
l~
fll'jll~'j
Cll'VlI'li'W
dd
'~:lJi)l'Jg;
oropharyngeal candidiasis Vl I 'W fl~:IJ
echinocandin
'fflm'jt1tJl'lJl
o
,
•
~
~ 'Wmru refractory azole-resistance 'l1'jClmru'Vl:IJfll'j\?l~I'liCl~'WII'j'l
1'li""1"1
..:'::!
d
t::1dd.
C>
1~'W~'W
Invasive disease fld'j.w1l1'jru I'll l~ ~ll tl~fltl(;lCl:IJI'W ~l'lfllV~tJ'JVClClfl
Redbook 'JlDtJ1] fl.fI' 2009
nfll'jfl~1'Ji:l'lf1111'Wg;tJl'UCl'l
IDSA guideline '0'1
lJ fl.fI'. 2009
0
oj
~"v
d
I~VI'j'J'~'ff~
q
~
"v
'"
:II
~ "I "_'I
posaconazole IlJ'WV1'ffl'jCl'l
l~ 'W~lJ'JV immunocompromised
')
Varicella vaccine:
d
'~~'WI~Cl 'l1'ffCl~fl~eJ~fltJ
,
'I "
,
mm'jml~'jmg;'illtJ
~
'UCl'lfll'j~~I91Cl\?ll:IJ'[j'j'j:IJ'lil~) l~fl"h;'fflm'jt11tl
"-'I"
'1"~
0
1l~g;~~fll'jfl~i):lJfl:IJfl'W'UCl~NlJ'JtJm'Vll
'U
q
cu
9
d
l'Wmru'UCl'l
..
:II
v
neonatal invasive disease Vl amphotericin B (AMB) V'lfl'lllJ'WVl
,
~
d'"
9"Vd
~
'li'W~II'jm~WClfll'li 'Vl'l'WCll'il~'illJrul
I"
d
'l1 lipid formulation '1"1
~ 'Wmru
~m:IJ1'jt1I'1~fll'j~~I~Cl~t'W'l19f'W fll'j~~I~Cl~'jg;tJtJtl'j g; [(1'Vl mm
"
'
=
I'li"
CleJfl '1-lJ1'1 ~" fIl'j 9I'll'Vlf1~:IJ
echinocandin 9l'Wl~fIll'jfllflV1f1d'j
oj
I'i''JVfI11m g;1JV1'jg; 1'1
invasive disease
'" I 'Wfl~:IJ
'
'I1'jeJtJl
llftg;I11'Wl'WCJ~l'lUCJV
3
1:ltl~lt1 l'UmW
9 "-'I
dd
v
oj
'"
_I ~
1'W~lJ'JV'Vl:IJ'jg;~tJl:IJ~I~Cl~'Ul'JlJfll'1
echinocandin
tJl fluconazole
dOL 'l11'lillJ'W'U'Wl'Wll'i,fl
"9 " :II
IlJ'WtJl'VlIl'Wg;'Wl
:II
(amphotericin B 1~'WVlrll'jCl'l) 1l~g;'jg;tJg;nml'Wfll'ji'flEIll,jfl1'j1'11
fl1l 2
iYtl~111'l1~~'iJlfl~m:lJl'jt1r11~~I~Cl ltl'illflmg;~WI~Cl~ 'll'i' hj~
~rllf111]tieJfll'j,flmtJfldl'lJ~'W'l 'il'UCl~
~tl ~fl'jCl 'l~'l11'l 'll1llriCl1JI'1'j'l1m'W '11'i'i'tJ 1f1q)'Wll~'J n'ilg; tl,jI~'W I 'jfl
echinocandin 'l1'jCl lipid formulation AMB
~'lU'W I 'Wtl'jg;I'Vlfl''ff'l1i'~m:IJ1 fll~~~fllJ 1l'Wg;tJ1I'W1] fl. fI'. 2007'l11 vari­
'jg;tJ::;nm1'U f)l'j ~flEil I'W mwVi 'I,jij metastatic foci ClVl'lUmJfl1'j
I,d
cella vaccine 2 1'U:lJllfll~fl 'W'!'Jfl'li'J'lCllQ I'WCl~'illfl varicella vaccine
2
V'l~~I~'W 1flq)'W'Vll'lI~Clflrll'l1i'tJl~fll'VlV
tl'j:;l'Vlfl'l'Vl tJfl'l~ Cl 'l'~ 'ill'j ru 1'j lfllVl'W 1'i'1tJ
l'j 'li1 V'W lI'i'mj'll'ilg;nCllflWWeW
oj
oj
2 1'U:IJ
~
fld'j~'ill'j
,oj
v
I'
~
v
fll'j.w'illJru 1hf'1flq)'W I 'l1!Cl
"_
I
oj
I'dCl'l'illflij ~ I 'Wl~ fll~ flCll'ill ~:IJe.lD~ fll'j
ru'UCl 'lfll'Jg;ifl'il lfl HI
d
~
9JQ.I
~ lil
'
Pertussis: 11J'W"1';ifl'W l~tJ'Vl'J Itl'Jl pertussis
typical
I~V1J~n'li'J'l
v
v
'"
~ n!'W
Q
Q.I
whoop eJ\?I'jlfll'j
~
Cll'Vl
ddtl"
1Jflll1~'jfl9fCl'W'Vllfl~'U'Wfl:IJ ~mfl
9J
d
Co
.J
1'li'W respiratory failure, secondary pneumonia, pulmonary hyperten­
sion I~'W ~'W 'il 1fl fll 'j ~flEll~tJ 11
1J 'il ~(Jl~V 'l~ rllf111]'U Cl 'I fll'j dl~
'"
d
d"
pertussis I'W'Vll'j fl '1~llflfll'j'Vlm'j~l:IJCllQ'WClV
, J5- J9 '0'1lJ)
('jg;'l1'Jl'l
fll'j~m'j~liiCllfll'jtlClm'W 1'W:IJlflfl1l
I~Cl'l'illfl'Vll'j fl~CllCJ'W ClV
7 1'W
•
fl1l 2 l$ieJ'W V~'l,j'ffl:lJl'jt1\'l~1flq)'WtJCl'ltl'W'M
tJCl~tl'W~,.fl 'M
'Mllfl
primary series
I 'Wl~flCllQ
q
ll~g;
0
~'lU'W:IJl\?l'jfll'jfll'j
fllmi'lJfldl:IJfl'jCltJfl~:IJ'UCl'lfll'jij~1flq)'WDTP
oj
mg;~'W I 'W1~fl1V~'W
q
9 "
oj
2 I~Cl'W- 6 lJ fIl'jll'Wg;'Wg;!'l1 Tdap 1'U:IJ
ClltJ 11-12 1]
q
'0'1
'"
fll'j'~'ill'jrul hf'1fl9i'Wllf)tJflfl~~Cl~cu
q
, 'I
I
_'I
~
'jCltJ'l 'Vll'jfl ClVl'l 'jfl\?ll:IJfllJ 'l1'Jfl9f'WlJeJ'lfl'W pertussis Ilfl'l1tlJ~
~
~'l " :II
I 'WlJ'il~tJ'WflV'l:IJ
~
~~ "d
1'1'lfl'j'ji) 1l:IJ'Jl'ilg;:IJ ~llJ'W contraindication
1~:IJ
oj
"v
d
v
,
•
v
u
"
,
Q.f
Q.I
IlJ'UCl'U~1Jll'jfl
IWg;
1:l'l.l~ lt1m1''l1l1fl~ 'ffl:lJl'j t1 r11 ~~I~CJ 'l11'11:IJV1 '1 'I.l 'ill fl mg;llm~{)V1
•
Congenital CMV infection:
v
oj v
r-.i
I
r-2
0
0
d
UI
:lJfll'jfl~l'Jt1~mll'Wg;'WllflV'JfltJfll'j
•
"
V
congenital CMV infection ~~'ff~lJ 1~~'l'W Cll'il
I 'l1fll'j'jflEllfll1g;
I'jI
~'ill'jun 'l1fll'j'jflEll~'JVVl ganciclovir 'li'W~'\l~ (6 mg/kg/dose '!'Jfl
_1~"Vd
v
~
I 'W1~fl'Vll'jfl'W'WCllfll'j:IJfl
~
1,j~ClVV~tJn
catarrhal i'W
I '1
l'UlJflEll\?l'J 'W 1'j~~VltJl~'ff'l
"
II'Wg;tJ1111Vl I 'W fI~:IJ
~I
..:!
:II
Cll'illl'Wg;tJ1hf'H'I~'W fll'j \'l~I~'lJ~'ffCl'llriClCllQ 4-6 1]
'hj
~'Ul'J~lIWg;~Cllfll'j ~'Wll 'j 'l:lJlfl
ru llmg;\?I~ 'ff'W 'il ';i1:IJfltJ ~lJ flfl'j Cl'l'UeJ'll~ flllJ'W 'jlV1Jflfl (;l
rll'l1i'tJ1fl9i'W 'j1:IJ Mumps-Measles-Rubella- Varicella (M MR V)
c;;
tJ 'Jv~ih~~I~Cl
12
~
'jI
Q.I
~'J 1:IJ'l) 1~'Wnm'Wl'W
6
d
iYtl~lt1 I'W'Vll'ifl~ijCllfll'iIWg;n
CNS
,:f~dl~Cl'l11'ltl 'j g; IV'liU'l 'W fll'j ~~ fll'i If)~m 1:IJ~ ~tl fl~
invol vemenl
'Vll'lfll'j llPW'WIl~g;,;r\ilJ'Wlfll'j~mQ 1-2 1] fl'J'j.w'ill'jru 11~'W'jlV1Jflfl(;l
'1 :IJ"1"~1l'Wg;'Wl I'l1'VllJfl'!'JmltJ
"
d
I'WCl'l'illfltJl:IJN~'Ul'llflV~flCl'W'Ul~:IJlfl 'l11fl
0
d"
d
,
"
1l~'Vl6.w'ill'jrul'ilg;MtJli'flEil fld'j~tJl~:lJtJlfllV1'W I l$ieJ'W'l1~'lfl~Cl~
fll'j.w'il 1'j ill 111'Vll'j fl~ ~ fl11:IJ ~~tl fl~ 'U Cl'l fll 'j '11PW'W1-¥;tJ ~ ClV 1 ~l~ V1fld'j
,
,
.
'ilg;~~ClVI 'W fl~:IJ'Vll'j flVin CNS involvement ~~UtJ1ll~'W'1j'Cl,j'l:jf'UCl'l
~
0
fll 'j i'flEll'l1!
Cl llJ
,
N't;V'J'liltlJ fl ~ 1111
u
'lJ
I'W fll'j
~flEll~ l'W:IJl fll 'j i'flEil
,
N
dd
~~l"
dd
'VllJfl'Vl'lJfll'Jg; congenital CMV infection 'Vl:IJ CNS involvement :IJ
~
'j'J:IJ~tJ'JVfl~:IJ~'lfl~l'JWl H ~'l,f'W I 'W fll'j '11 l:lJltl'j :;Qfll91H' fl'l~Cl~~
=
:II
fll'j "~'il l'j ru lllJ 'W';i lV1Jflfl ~
I'W fl'jW'UCl'l'Vll'jflfl~Cl~ tlCl'W r11'l1'W~~~~I~Cl CMV
fllV'l1~'l
fl~Cl~ eJ'l "llJiJfIl'j~flElll~V'JtltJfll'j hj'tJl~l'W '1 'Ji'[(I 'WN'tJ'JtJfl~:lJd em
~
'"
9"
v
"
~'ill'jrull'l1fll'j'jflEll~lV
:II
ganciclovir IlJ'W'jg;Vg;nm 2
tl'i:;lli'W~tJ'JVJl t11~~'WCll'il.w'ill'jru 1111fllJi'flEll~eJBfl
0
v.
I
~
'ffu~lml~g;
1-2
iYtl~lM
Treatment of uncomplicated gonococcal infection among
.
.
,d
children beyond the newborn pedod and adolescents: l'lHn'iJlfl
~
d'
QJQ
~D\91fll'HU'IJeJ':]I'lm
gonococcus
9
I
\9IeJ\91eJVl l'Wfl~)J
~
I
fluoroquinolone (FQN)
mfl~'W l'WtI'iJ~DWJl'l'Wfl~)J FQN \lfll91\91eJeJfl'iJlflJl(Jfll'Wl~II'W~'I11
~
9 "'9 "'9
1'l1 I'll l'Wfll'J'JfllJl GC
9 .1
~
~
'"
l'WlJ'J~li1f1'fl'm~eH)J'JfllUm
(2007) Vl'Yl
extended spectrum cephalosporins eJl'Yl'"
1'll'W ceftriaxone, cefixime lW~ cefotaxime !\9IV ceftriaxone U'W~'I11
9"'9
~9~
l'WeJ
9JQ.lO
0
1'l1fl'eJ\9Ifl~eJ':]flDmU'W~'Wl'UeJ~
'i
0
'l '"
I\9lVU'W~'Wl 'l1
prophylaxis
American Heart Association (AHA)
a
l'lnn~flJtu
'"
dental procedure (VflWflfll'J
'l,r'l'W flJ Wtf\91tl fll'J~l~Vlrl1J'J~DD'Yll':]I~'W tll'l11'J
'Yll':]I~'Wtlfl'ml~ 'l1~ eJ
'Yll':]l~'W'l11V'l'iJ)
hfltfl'l'iJ~fl')Jm'J'W'iJl'Jtul'l,r prophylaxis 'I~un flJW
' r ' V ,
""I '"
'9
'
11'W~'Wl 91'l1"'9I'll \9IllflVll'Wfl~)J
o
d
Prevention of bacterial endocarditis: iJfll'J tJ i'1Jl,j~v'Wf11U 'W~'I11
0
a
'9
d
0'l'"
"'9'
aa
'l 'IIfl'~UlJ~fllJ~eJ)J
"'''' .1
.1
'l 'Wfll'J'b'eJ)J~'W'l11
' ' ' ' ~ 91'iJ
'Yl)Jfll'J
endocarditis
mneJ'W
'I \9Illfl
'" ,
"'.'1
'"
'"
~lJ1V'YllflV)J
infective
dl'W~tJ1Vtfl'l'\l'Wfllm~nl1U\9l~fl')Jm'J'I~
'1 "I '"
"'.'1
'i
~ 'l '"
'0 '"
~ a
d ~
~lJ1V l'Jfl'l11 'iJ'Wfll'JU\91flll'W\9I'15'W\9Il\9lVl'YlV':] )J \91
I'll l'WflJtu GC 'IJeJ~'l'Jfl\9llU'l1'W~l'Wl\9lfllW~~ 1'l1l\J cefixime 11'W~'Wl 'II
prophylaxis
'l'WflJW uncomplicated GC 'IJeJ.:] cervix, urethra lW~ rectum lW~
~
'~""1 'U ( 'I'~
~I
'~""I 'U)
'JDfll'JNlI'l\9lUfl
)J'W1J'Jl)J palliative shunt llJ'Wfll'JN1\91\91Ufl
U'W~'I11'l'lf''l'WflJW GC opthalmia, scalp abscess ll~~
~{j lV! 'Jf11111'iJ'Wfll'J ll~ nllU\9I~ Mi'Dfll'J r-h 1'1\91 uti"l 'Ul~ VD~eJV~iJ fll'J
'l'lf'~,:]UtJ~fltJ~eJ)J (U'W~'lJ1'l,r prophylaxis m'Wl~'l'W'J~V~nm 6 l~eJ'W
U'Jfl'l1~':]fll'Jf-hl91\91uti"l'U) ~{jlV! 'Ji'ltfl 'l'iJ'Wfll'J U~nllU\9I~'I~i'Dfll'J
N1l91\91U ti"1 'U U~ lU~ iJ.:] iJfll1)J N\91 tJ fl~ 'l1~':] l 'l1~tl eJ ~'l 'W 1911U '1111.:] ~ iJ ~.:]
cefotaxime
disseminated GC 'l'W'Yll'Jflll'Jfllfl\91 f11U'W~'I111'Wfll'Ji'mJlm'iJU\91fl~1':]
rl'W
'ltJ\911mf'W~~vm lfll'J'WDl~eJieJV1~II\91fl~1~rl'W
'l tJ
Measles and vitamin A: 'iJlflfll'J'Jlml)JeUm,J~ !\9IV Cochrane review
tJ~fltJ~HWeJV lW~vr{jlVltJ~V'WrilVtfl1 'iJ~iJtlw'l11i'Wtfl 'l 'iJN\9ItJfl~
U
'WD11 V\9\'Jlfll'J\911(J~iJmll1l9l'JJ1'\llfl!'Jf1'11\91~\9I~':]'\llflfll'J
~~{hv'Mi'Di\911~'W A 1~'W'J~V~nm 2 l\!~\9Irl'W (fll'J'l,ri\911~'W A
~
u
~
2005
lY1V~Uri I dose 'hilfl\9lN~) U'iJ'iJD'W
eJ~rlfll'JeJ'WllJV hfl ll'W~'I11'l,r
,
Mi\911~'W A un~{jlVl~fl'I'JflJlv~{jlVl~mr\9l!\9Iv'lJJiJeUeJ~lrl\91 'lwd
'IJeJ.:]tll~ ml)J~'Wll'J':]'UeJ~hfl 'l1~m.h~mf1'~mrY(Jtl~'IJ'Wl\9l'IJtl~1\911~'W
A ~H'l~llfi 200,000 IU cll'l1i'Dl~fleJl~mflflll'l1~eJl'l'ilrlD 12 l~tl'W
.
.
Susceptibility of pneumococcal isolates:
d
N~fll'J\9IeJ(Jl'UEJ~l'lleJ
.¢I.
iJfll'JtJi'DltJ~V'Wfll'JUtJ~
,
r-i 'l '"
'" ~
Streptococcus pneumoniae l'WEJ
'l1fl'eJ\9Ifl~eJ~flD
f11U'W~'I11'l'l1JJ!\9IV Clinical and Laboratory Standards Institute (CLSI)
~':]lW\9l':]l'W\?ml':]
100,000 IU 1'W'Yll'JfleJ1V'J~'l111':] 6-11 l~eJ'W lW~ 50,000 IU 'l'W
'Yll'Jflm~'l1'eJVflil
6
l~eJ~ !\9I(J'l,rl'W~~
Drug and Isolate Location
I i'lf.:]
~\9I~eJrl'W
2 1'W
Susceptible
Non susceptible
(mcg/mL)
(mcg/mL)
Intermediate
Resistant
~ 0.06
O. I 2-1.0
~ 2.0
~ 2.0
4.0
~ 8.0
~ 0.06
None
~ 0.12
Nonmeningeal
~ 1.0
2.0
~ 4.0
Meningeal
~ 0.5
1.0
~ 2.0
Penicillin (oral)
Penicillin (IV)
Nonmeningeal
Meningeal
Cefotaxime OR ceftriaxone
Prevention of gon?coccal ophthalmia:
'" _'1
~
'"
n.
'l1 VeJ \9I\9111~)J 'lJJiJfll1)J ~ 11 ~'W
'1 '
0'l '"
~
~
lJ'iJ~D'W
)JU'W~'Wl 'l1'l1VEJ~
a
'~.I
'"
.
D'YlViiJ'l'l1JJ'l'W Redbook 'i),Duu'Mun Fusobacterium infec­
U~~
Vl silver nitrate l'WeJlJeJ':]fl'Wfll'Jlfl\91 GC ophthalmia tlfl\91eJ llJ Vl'Yl
tions including Lemierre disease, Human Bocavirus
""1 \9IUfl
'" ,0.5% erythromycin ointment 'l1'JeJ
'" I % tetracycline
ophthalm ic solution ~':]Vl~':]fl'eJ.:]iJtJ'J~iY,~ ~m"'H'I'i1l'VlV)Jrl'W'l'W fll'J
viruses 'l 'W~li''iJ~ 'lJJ'UEJfl~ll~':]I,jeJ':]'iJlfl'WD M'lJJDeJV 'l 'WtJ'J~l'Ylf1''l 'Yll'J
9 ":"1
U'W~'Wll'l11'll
o
iJeJ ~ rl'W 1 'Jfl
1'W fl'J W'Yll'J flU 'J fllfl\91 ~ fl~eJ \91 'iJ 1fl)J 1'J \9Il~ 'l~i'D fll'J
Polyoma
vrfl''W 1'iJ fl'1)J l'Jtl'l11V l'Wl ~)Jl~)J 'M'l'W Redbook
~
lU'iJ'ilvl1l~'W GC u~~m'J\9IliJ.:]'lJJ'l~i'Dfll'Ji'mJl m'J'W'iJl'Jtul
Mfll'Ji'mJl'Yll'Jfl~lVfll'JMceftriaxone ~\9IleUlfl~l)J I 1~fl' U,j'il
'Yll'J fl'iJ ~iJ.:] 'lJJiJ eJ 1fll'J
9
~
l'Wfll'J'JfllJl
n~ 'J l~ flJ Wli'Vl'l1VeJ \9I\9111Y1V,:] eJ Vl':]I~V 1 'lJJ'l ~N ~
'1 "'~
~
'"
a
'"
U~~'l11fl'Yll'Jfl \9I'JDfll'J'JflEll\9l1VfllH!\9IVllWl fll'J
I. American Academy of Pediatrics. In: Pickering LK, Baker CJ,
Kimberlin OW. Long SS, eds. Red Book: 2009 Report of the
Committee on Infectious Diseases. 28th ed. Elk Grove Village,
IL: American Academy of Pediatrics; 2009.
~HnUf)l'Hl1 l~f1'lflI'JDl~ 6 1J 10 l${eJ'W Jll1Uf1 21
1J~f1fJll~emieJlJJll'vdleJ~~fleJ~lu'UllmlJ1\91 l~lJ
ci~m
i1'1 11i\91 eJlJ'ff'W eJ~~eJ nl'l i'nEJ 11'lJ'J1il1nl 'l \91 'lJ'il 'I1l'fflml9ll ~eJl ~lJl~lJ I~H rl
iiloU' Mi'lJl'Jl
CBC, ESR, CRP, PPD, EBV, CMV, HIV l~'W~'W I:J~eJI'JH'W~U1 M
nhf1i'lJ
1Jfi1hw~lJll1ml'J'lfu\911unm 3 iY1J\911'l1
o
1J'i~1fl 3 iY1J\911'l1rleJuiiloU' iineJu~rwl'hw'\mmlJ l~lJ fleJlVI'J~I1J
~l'W'Ull 11Jl'llJH 'W'VlcJ~ h ~lWl1Jl'lmi~'I1~~ I~i'lJl'Jl amoxicillin­
Q.I
Q.I
iY1J\911'l1H'l f1m:1~i'lJ1J'l~'Vll'W1'J1Dlnl'J~~'W
')1
d
~ .J d
H'l~ f1 eJ'W 'Vlfl eJ lJ llH'illJ'U'W eJ f1
loU''l\91'l~
'lfl~
8 1'W
HI91I91 eJmii "loU'v f1
l~\911'W'l~
(l50 lJf1.) I
,~
~')1
~
~lVn'W
~
i'lJ1J'l~'Vll'W 'l~
ii~'WHI'I~
2
I"
'I1'l~'I1V\91Vl \91
~
d~;V
10 1'W eJlnl'lI'l'\J'W
~
,,~
'lfeJ'W'lfll'W'l~
clarithromycin (l25 lJf1/lJ'l.) I
Q.I
H'W'VlcJI~l1J~V'WVll~'W
r1'W\911lJI'l1
f1eJ'WVlJ'l~
Q.I
nB'W~fleJ~l'W'\Jlll\91~'Wvf1'
~
~ ,I
fl'l~ 'llJlJ'l~'Vll'WVl
'1"1'1
""I '\J'\J'WeJf111'l~
"« ""
lJ
~
~
2 1'W
""
"", I'"I'IH\9I'WeJV
" t1leJlnl'l
"
I\9"1 ,!eJnlmn\91nl'lH'W'\J1lJn~lJ'WlJ
I
BV1~~'Wm ~
d.d
d
9l.d
~eJlJJlmtleJ~~1'1eJDm'fflJl'Wl~f1 cil'Wl'11t)jl~'W
process (feJV'l~ 87-100)' H'l~iTf1'il~'I1lVI~W~Jllvl'W 4-6 iY1J 1'1 1'l1'
,
~1
'Wl'il~llJ'W
amoxicillin
~r
dd
I
llJ'Wl'Jl'VllJ'ffl'WN'fflJ'\JeJ~
.
amoxicillin
1'WD\91'llcil'W~ll\9lf11911~ iinl'l~f1fJl1J'l~rr'Vlinll'l
, '"
clavulanic acid 4: I \9Iell'lfeJ Staphylococcus
H'l~
aureus l'llJl1 minimal inhibitory concentration (MIC) '\JeJ~1'J1
'fflm'lt1erlJ5~l~eJI~ H~l'Jl~iiiY\91cil'W~'W
"1
,
l'lf'W 7: I
~
I
H'l~
benign
9J
lJN'W'Vl'l1'W ll1'leJl'leJI'I1V
Q.I
~.:i
d
0
acute otitis media
philus
~
infllle~zae lW~
'I1~eJ
14: I ii
Q.I
'\JeJlqJm1'lf1fJlnl'l\9l\91I'lfeJ'Vl'ffll'lW'\JeJ~c ommunity
'"
d
'lHllHl'YIfl1'i'YI'illJ
'"
~I non IgE mediated hypersensitivity \91~'W'W'fflm'lt1
~ ~
9 "
llJ'W
!'If
clavulanic acid
'j}
,
'UeJ~~eJlJJlmtleJ~11~nmlJ
'"
'"
cephalosporin ,!\91l'JlJ
maculopapu!ar rash 'I1'leJ
Amoxicillin-clavulanate
'UeJ~Vl
2 1'W
extension
1'lJ'l HVln~lJ~'W5
1'W
IV
'"
benign 'I1'leJ malignant process
IgE mediated hypersensitivity I:Jl'l1'l1~1'J11'Wn~lJ beta-Iactam
lW~
d
"
..d
~~'\J'WH'I'j'VlV l\91l1J'lV'Wl1J'W cefuroxime (250 lJf1.) I llJl'Il'W'l~ 2 m~
d
.d
ll'WllJ'WN'WHlJlJ urticatia
H'W'VlcJ'1~~~~lVVl clindamycin
fl#~ l~f1i'lJ1J'l~'Vll'WI1il~ulVlmfl'W
3
"
I '\'J" 'lJlJ\9111'J
'j}.?1
fleJlPll'W'Ulll\91'ilj~ CBC: WBC 17,900 cells/cu.mm. (PMN 73%, L27%),
platelet 370,000 /cu.mm., ESR 40 mm/hr
":1
~lJ11'J'VlH'W1'J1
Vl penicillin
lJlml'il~h~'WVl1Jl'll'llJl~'Wl91tJlJJlmtleJ~~
10 1'Wl91eJm
I lJ'fflm'ltHWn
'
vndJ'W'l'W1Jl~'llvvi'll~eJ~
M
I
QJ
m~'Wl'W
2
llnl~
11Jmf1rvhl'lH
~
'j}
'lfeJ'W'lfll'W'l~
clavulanate (457 lJf1./5lJ'l.) I
rI
<J}
Q.I
1~leJ'l\9l'l1'lf11\91
'"
'illm'lfeJ
Streptococcus pneumoniae, Hemo­
Moraxella cartarrhalis
.c...::!:i
acquired pneumonia
''''''
I1'"1 1l\91'I lJlJ'\JeJlqJ'lf1l'l
67
'lnEJ1f1l'l\91l'1l'lfeJ StaphylococccliS allrells .
'fflmI911'Wl~f1ln\91 'illf1nl'lfl\91l~ell~'W cil'W '1 'I1ru l~eJ~I~'W 'fflm\91H1J~
r
U
$I
( j ,
o
dd
QI
Q.I
q
.::\1
\911lJ\911H 'I1'W ~'VllJnl'l eJ m 'fflJ 1'1 ~ 'W­
~eJlJJlmtleJ~~fleJ 2 oU'l~ Dm'ff1Jl~VlJ'Wt1'W (Jllvl'W 2
l'llJ1JeJV~'ff1'l, Inl'l'illf1nl'lfll'll~eJ I li''ffl'W'Vll~l~'W'I1lV 1'ilcil'W
I.
iY1J1'l1'l1)
~I
cervical lymphadenitis in children. Am Fam Physician 2008;78:
~
'
9'
""
9
gitis "1 \91\9111'
"" J
",'I
!'W~lJ1V
lJ'WllJ'W'ffl'W !'I1t)j 'WeJf1'il1f1'W'!'m
1097-8.
gr. A Streptococcal pharyn­
2. Swanson OS, Edwards MS, Torchia MM. Etiology and clinical
~eJlJJlmtleJ~~1'1eJ.u1~l~V1Dm'fflJl~VlJ'Wt1'W
2.
manifestations of cervical lymphadenitis in children. www.update.com
(i1ll'Jl'W 2
~
QJ,..1
rI
'j)
'leJl'J'l~
'fflJl'Il'l1)
~
.t:::\
40-80 lf1\91'illnl'lfeJ S. aurells
lW~
gr. A streptococcus
I" ,
'"
'Vll'llJ'leJ~'l~lJl \91lln Streptococcus eJ'W
'j/,
~
,
I. Dulin MF, Kennard TP, Leach L, Williams R. Management of
t
a!
'ffl'Wl'lfeJeJ'W "1
"1
H'l~
enitis in children. Seminars in Pediatric Surgery 2006; 15:99-106.
anaerobes
iTf1ii1J 'l ~ 1fl Vl 'WN ~ llJ~ lV
~eJ~JlmtleJ~~1'1eJ 2 .ul~Dnl'fflJlfeJi'~ (mf1f111 2 iY1J\911'l1)
3.
3. Gosche JR, Vick L. Acute, subacute, and chronic cervical lymphad­
,
d.
4. Swanson OS, Drutz JE, Kaplan SL, Friedman EM, Torchia MM,
Torchia MM. Diagnostic approach to and initial treatment of cervical
191
l'lfeJ'Vl'WlJlJeJl'J I'IHf1 EBV, CMV, TB, HIV, Toxoplasma, Syphilis 11J'W\9I'W
,J d
r
d
I
~,
,
0
6l
')1
d
~
d
.d
QI
cv
\91eJlJ'W1m'leJ~'Vll'leJ'\Jl~I\91VleJm'fflJl'leJ'l~
,
4.
')1
,
(lJ1f1nJl
2
I" ,
'fflJ\911'l1) l'lfeJ'VlV~lJlJeJl'J \91Hf1 Non tuberculous mycobacteria, Bartonella
~
Q.I....
I
cI
6l
<::.i
~
henselae,
'WVlJ'Vll
9l
Livingstone, Philadelphia 2005
T~, Toxo;l~sma
cit
0
61
dcv
l'Jf1n'W'lll'J'Vl\91eJlJ'Wll'l1'leJ~lJ'lf1EJru~
,
of Staphylococcus aureus towards amoxycillin-clavulanic acid,
fluctuation 'If\91l'il'W 1'11'l
'"
i1'l\91eJlJ'ff'WeJ~~eJnl'li'nEJ1JllI'J1'W
6. Skov R, Frimodt-M?ller N, Espersen F. In vitro susceptibility
Q.I
~,
I'lJI
'Vll needle aspiration l'WeJW1'l1'WeJ~m\9l'lJ'ill'Wl~l'lfeJ H\9I
l'Wl~n~iiDlnl'l "l.u 1Jl\91mlJ 11\91~feJ'W~~eJlJJ1mtleJ~~1'1eJ9f\91I'il'W
iTf1 1"r'V11J fi1h'W~1'1 'l eJlJ 1'1~lJl ~eJ ~ 111 'il~l ~ 'W 'fflml9l cil'W 1'I1t)jl1J rleJ'W
o
Principles and Practice of Infectious Diseases, 6th edition. Churchill
,
'" '" I'"\91lln
l'lfeJeJ'W"1
nl'l\91'lJ'il iU'il'itVI~eJ'I1ll~eJ~h~'W'fflm\9l1
,
, 'W'l~V~ll 'lniTn '11i
0
5. Andes DR, Craig W. Cephalosporins. In Mandell, Bennett, & Dolin:
t
~
.c:::.
lymphadenitis in children. www.update.com
'"
48-72 il IlJ~
"
~
!\911'J1~1
penicillin-clavulanic acid, dicloxacillin and cefuroxime. APMIS
2002; 110:559-64.
7. Easton J, Noble S, Perry CM. Amoxicillin/clavulanic acid: A review
ll'W~Ull"r'~eJMmlJ
of its use in the management of pediatric patients with acute otitis
10-14 1'W 'I1~eJeJtimreJl'J 5 1'W 'I1t1~'il1nDlnnl.u 1Jll'lmlJHI'I~'I11I'JI1J
media. Drugs 2003;63:311-40.
.
•
j'@GMENT,iiES
ula~
a:aXICillinIcla
at'
I
powder for oral suspension
~ES can cover major pathogens in ADM and sinusitis
1
,2
Streptococcus pneumoniae,
(penicillin MIC < 4 Ilglml)
Haemophilus influenzae
Moraxella catarrha is
GlaxoSmithKlinc
Wll1fqrJJI'1tMu,LI'ri 11"_ 851/2552
AES 01/06 TH09.-211OMl9
bh'lfhU"l1tJtl:lDlJfIlilslLiiwtulen"11h~a!"a::UIO.,.,,;,nuU1
Tl
-­
>SFf.AS.aUWS FfSIWthJ~" n1A51j1vCl~b5nEJ1
•
1
Aru=IIWnEJFl1CfVlSASS11jWEnU1Cl UP\VlCl
1 fl:nU(11:lJ11'tirl'f) 1~ Lnl1lfliJ AJJnU~(11:lJ11'tiiJ'f)~nu
11'fl
q
S. pneumoniae rl'f)hflU'f)tJh.l'Vll1'n, L~nd~n LL'~:;
~
~(1--1ll1tJ ur,y~tJl um1'rl'il hfl~~1 ~ru~(1l1l'lJ'il--1b~'ild ~'il bbmj'1i~ ~'f) bL'ilU~U'il~~iJmlJJ~ILvn:;~mL~tl~~
~
'tI
Ii
q
~
'\J
L1JU~I'llYl~bb'1iflm h~ iJflrum.J1:wiLLlULb'f)U~Lr,yU'llUl1lbbl1ln~l--1nu
"
q
vh 1~(11:lJ1l'mLU--1L:U'il1a1'il~I--1UmJ 91 :nhVi'tJ1J I fll1JJ1'ULL1'--11 u
m1'rl'il hflll1r,y~unU'lJUll1l'lJ'il--1LLfltl'1i~ :nhVi'tJ1J 3 iJLbfltl'1i~'l,ljU1
~--11'Ubb 1'--1~(1l1l ~lu:nhVi'tJ1J 3? bbfltl'1i~U1--1~--11~1'UbbN LLfltl'1i~
r,y:;Yll'1,1jUl~trmiml1'~uilull1ltJ alveolar macrophage L:Ul1l
b~'f)l1l'lJl1 PMN lULdm~'f)LL~:;L~'f)l1l ~Ul1b~'f)~'f)~lUL~'f)l1lr,y:;
tru~--1m1'~uilull1ltJL:Ul1lb~'ill1l'lJl1:lJ1nnl1L~'il~'il~l1l1JJLdm~'il ?h
L~'f)L 'ihm:;bb(1 L~'f)11l1 uflu~1~iJfliJ AJJnur,y:;'5Ul1l1'ltJ:lJ1n L'V'l1'I:;
L~m:; Lr,y';b1J L~JJ~lUdU'il~I--1nl1lL~lYll1 ~Lil l1l\l11'~l1l L~'ill UL~'ill1l
'I,Ij;'-'f)1 UL~'f)~JJ(1JJ'f)--1 L;'-tJnll invasive pneumococcal disease
(IPO) 'V'lU1a11J'iltJ1UL~nll1tJ~lnll
2 U LL~:;iJoJJ'ilJJ~m1'~'ilm
'lJ'f)--1L~'ilL~JJ~ur,yULLluub1J'l,ljl1um1'fmn
q
~
'I
'I
~
'U
'U
q
~
~
heptavalent
pneumococcal
iJmnh
conjugate
pediatric
vaccine
PCV?
m1'~boJJ11UUb1J:U1fl:nU'I,Ij~mLv1--1'll1~ (EPI) lutl1':;L'VlV1~l--1
'l nl1
20 tll':;LYlV1vi'11~n 1a1LLrl tll':;LYlV1 (1'1,1jfJ''ilLJJ';m LLflU1l1l1 '5~n~M
cJ*~bV1(1 LtJ'f)1'lJU U'f)1'Ll~ 'il'f)(1Ll1l1'L~tJ bb~::;b:un;nln bLlu~u
1~:nU PCV? - tll':;n'ilU~ltJ ? :nhVi'tJ1J~'V'lUrl'f)hfllu
L~nJJln~~l1ll'u~'l,ljf~'f)LJJ';mbb~:;"hul'1,1jruLLluL~'f)~m.n ~'f) 19F,
q...
~
14, 6B, 23F, 9V, 18C, 4
'I,Ij~--1r,yln~iJmnh1fl:nu PCV? boJJ1:lJ11oll1utl1':;L'VlV1
(1'1,1j¥~mJJ~m
~--1bb~U fl.V1. 2000 l~L~nYlnflu~iJ'il1t.JU'iltJnll
...
q ,
5 U 'V'lul1m1'Lill1l IPO ~l1l~--1 1~L\l'V'l1:;LL~luL~n~1a1¥u1fl:nU
LL~iJm1'~l1l~~ 1U~~--1'il1tJ~1~ lfltJ1a1¥u1fl:nUa11t.J 2 (herd immu­
nity) L'V'l1'l:; L~n~1a1fu1 fl:nU r,y:;~ l1l\l1l'LL'V'l1\ ~'il1tltr--1 ~1'\t1ru1J1
m1'~fliJ AJJnU~l:lJ11'tiiJ'f)--1nu IPO LUUbbUU~l L'V'll:; ~'f):nhVi'mJ
v1--1JU1fl:nu~iJ'l,ljmtJ 'l :nhVi'tJ1J LLlu~lutl1':;n'ilU~--1tllr,y:;iJ
n11=Bmv1ns::llalat>A1UAunluiJniJAunu~::6u~S1a
_
.
"1
U1n IWS1::lfit>~::I~SryIWU"1U~Ut>ei1\1S~AIS~ .hln tl1':;~'Vlfifll'V'llunll'iJ'f)--1nUll'fl~~U
~
q
q
q
~
~~
q
~
~
IOAn1siijAI8t>lUlat>Anst>lUl§m1'uaut>\I
.san::i1
•
invasive pneumococcal disease (IPO)
q
~
"
, ,
""
'1.1
"" "" v ~ l'll'fl
""
n1l'Y'lmn
bUlJl'::;lVlY'l'l VltlVllnm6]J'fl,mU
S. pneumo­
~'1lltJn1~"Vln~thtJ
niae
'\J
IPD
1'Ul~n~iJll1ml'fltlnl1
, PCVlO _ 70.3%
========~'~PC~V7~=~70~.30~Yo~~i!!..:..:~~
tJ3
5
,
16
¥ul'ih¥mn1ulH\"ImU1f1~~n'll "Vv:l'lf1'1nl'ru
.niJ'I,Aj'n'fli?1'ntlli?1'll
,
'\J'
~'16]Jf11Ufl~UVlf ~mUU~6]Jm'l,Ajl~mlv1'1'lll~hJvnl'l:Ui1
ll'n::;l1''1
,
'l,AjmU1'n~u 1 'U'fl'lm::;Vll"N~lDll'ru~'U li?1m~'fl~vhn1l'Vli?1~'flU
=
• PCV13 = 81.2%
14
'"...
"
OJ>
0
.,;
z
12
-
10
- - 1 - - - - 1 - - - - -21 ..,,.,-1---+----+-------;--1].----
8
-H~I%,----I-----+----:------+---...--
-
.''Io--II----I-iJ!.'%-;----+-----;.-.-
6
'l~:lJ1"VlnVlnm
, fl'U'fl'lUl'::; lVl m::;vdl'1l~'flUJJml flJJ 'I,Aj. Y'l. 2543 ­
'I,Aj.Y'l.
ilI1'flth'l
'l,AjUl1
serotype
("v1JJlt1D'Ilfl:TIu PCV7
1~un
1, 5,
tJ ~l'UdU~'l~U
2548 1'1JJ'J'::;tJ::;l1f11 5
fi'UdlflJJ
PCV7,
PCV 10
~lJ~l'Udu:nhVlm:h~JJ:lJ1n~u~n 3
ll'n::;
7F)
'U'fl'l
coverage
115
PCV13
'llUi?1
,
("v1:lJ1tJD'Ilf1:nu PCVlO
~l'U1u:nhVlm'h~JJ:lJ1n~u~n 3 'llUi?1 1~lln 3, 6A,
~i1t1'n::; 73.9, 77.4 ll'n::; 87.8 l?11JJ~1~U ('J'U~ 1)
19A)
ViiJ
~'fl
PCV10 = 77.4%.
V
•
Quellung reaction
.0
immunological
~1JJ1'ab1(i"1'a1"l1~"llm;'fl~l'rn::;'LIU blood agar Jlt.J1
~1.jj'Vl~~'flU~tl II '1)U~:jj*JJ~lJ fl11JJ~1 b'l,Ajl:; ~'flllflU'n'6'l6]J'1)'l pneu­
mococci Vln:'TIhYfmJ l~'1)"v1t.Ji?1U'flU~:jj~JJ'o'l'l1u~~lJnUl~'fl~~'l~tJ
ll?1'1"l:;d'1i?1uBmt.J1Uln~:;n'flUl{'ln 1 (precipitation) ld'flUl1'1"l~
20.0
:; 2O"k
~
"C
~ 15%
q
12.2
10.4
lOOA..
5%
0.9
0
0
"
~"
">
~1t.Jn?1'1)'l"V'rIVl'a'aY'lUfhK'l'lJt.J1t.J
10
,
q}
100 'Vh'lV;li4u~nBru::;f1?11t.J
li4u 1~o)fi?1l"IU
Mapled Irom Phoogsaman W. at 31. Vaccme. 2007:25:1275-1280.
sLJrt 1: A31UijnVEhll8a S. pneumoniae (;I1Un1SnS~Q1BVa\l
5rsnB(Jffi8IuucbuLls~naulu5A5u PCV?, PCV10 lIa~ PCV13
•
S~tfd1\1U W.A. 25430\1 2548
nl'J'~nBl1UUl'::; lVl Y'11VltJ f1~'l1"v1~ ~l~ i?1
Vi 11 W~1lJi~ tJ
4
,
~1u1"v1qJ8'1fl'llLlu
X
llflU~f1'1,Aj'fl'l'1)'fln (capsule swelling) "v1~'1)llflU~'rIiJ6]JUli?1'l"v1q)llf1:;
",'S'
Serotypes
V
V
" f>l
'1DUblJ'UfI1'a'Vli?1~'1)Ui?11tJ
4::o.qq
reaction
27.8
"o
~ 25%
~
­
"l
sLJrt 2: A31UijnVa\ll8a S. pneumoniae (;I1Un1SnS~Q1BVa\l
5IsnB(Jfi18IuucbuLls~naulu5A5u PCV?, PCV1 0 lIa~ PCV13
PCV13 _ 87.8% •
35%
30%
• Vaccine serotype (Sterile sites)
• Vaccine serotype (Non-sterile sites)
Adapl&d from: S.Snleungtung Vacc,ne 2010
S~I"i:j1\1tJ W.fT. 2549 0\1 2552
'\J
PCV7 = 73.9% ,
Sterile sites; n=64
Non'Sterile sites: n=42
'\J
ll~ i?1'l11'lV;~'rIU1nnUfI1l'Vli?1~'flU n1l'~li1'UllflU'n'n
lJ6]Juli?11"v1q)~'Ulti'fl~"llm~mili?1u5fWt.J1~n~::;il'1)'Ul{'ln 1 1u'I,Aj'1)n
~U~b'1rullfltJ'n'6'lll?11'vh1V;~'llt1V1m"v1 (refractive index) 'lJ'1)'lll~'l
'lun?1'fl'l"l'rlVlnf1UbU~t.J'UllU'rI'l1U
CJ
,
~
~
b'eln~l~'eh~~.:l
network
1. Park IH, Pritchard DG, Cartree R, et al. Discovery of a
l"v1lJ'fl'Ul~Wl'n:::iJh'l'l,AjtJ1U1'r1~U'1 hJJ~1tJ~n 10 llv1'l (l'fln'llu
6 llv1'l, ¥~Ul'r1 4 llv1'l) li?1m~i1~v1ln1'J'Vli?1~'flu1~"VlnWtht.l
,
,
new capsular serotype (6C) within serogroup 6 of Strepto­
pneumococcal
collaborative
~
~
IPD
~
~
~
'1
4
w:
qc:l
'lI
'Y~.Y'1, 2549 - nJJm~ufi
'Y'i.Y'1, 2552
,
ll'rl::;luul~'flill1mh'l "!lmu'l,Ajl::;u~nrum!Plnf11'1
and
indirect
effects
of
routine
vaccination
of
I
Uf1::; lJJtl1 lml::;"v1r-J'rIn1'J' V'lnBl lmn::; b'Uli?1nVlJJll1t1Uilt.Jn11
,
5 tI 'J'::;Wh'll~'flUlJmlf1lJ
coccus pneumoniae, J Clin Microbiol 2007;45;1225-33.
2. Direct
children with 7-valent pneumococcal conjugate vaccine
on incidence of invasive pneumococcal disease-United
States, 1998-2003. MMWR 2005;54:893-7.
~'1"v11i?1 ~'fl
3 Phongsamart W, Srifeungfung S, Dejsirilert S, et 01. Serotype
ll'n::;UUVllj'a ViU11 serotype coverage
distribution and antimicrobial susceptibility of S pneumo­
'lI'fl'l PCV7, PCVlO U'rI::; PCV13 ltlU~'flt.Jf1::; 70.3, 70.3 ll'rl::;
niae causing invasive disease in Thai children younger
(?11JJ~1~U (l'U~ 2) ;'l"V::;li4u1~11 PCV7 ll'n::; PCVlO
f1'J''flUfl'nJJ:nhVlmJ1~
lvh~'u U'rI::; PCV13 fl'J''flUfl'rlJJl
,
, ~JJ:lJ1n~u
4. Srifeungfung S, Tribuddharat C, Comerungsee S, et 01,
fI~'llVl'l,Aj"1
81 ,2
.1
UfI'J'lJ~lJ
""
3
I
'\J
~1ur-J'rIn1'J'~nBl'U'fl'll~'fl~lJ~ru~JJtWl~'fltJ1UD:;'hu::; 'l,AjUll PCV7
~l:lJ1l'b1f1'J''flUfI'rIW~'fl~~m.n
penicillin 1~~'i)t.J'rI::; 83 ll'rl::;
,
cefotaxime 1~~'flt.J'rI::; 100 l?11JJ~1~U
than 5 years old, 2000-2005, Vaccine 2007;25: 1275-80
Serotype coverage of pneumococcal conjugate vaccine
and
drug
isolated
susceptibility
of Streptococcus pneumoniae
from invasive or non-invasive diseases in central
Thailand, 2006-2009. Vaccine 2010; 28: 3440-4
Y;eJDelfy:il ... mmi1~fl~fi'll\lm~ n"'fli1.njl\llij1l~n'lll~
ri1i11fl'h~tu1'U\~!J1 ii1l~Hnm mlMy.U1
F7
'\\/~
~.
J
.
.
~m.Ji)nL'rl""~ltJq)<l""nl~Ji)tJl~
IInsu
UAUII .
IInsu
1
11 -To
l1nHfUJl1t1
UllTln
IIUaO\lU1UU
download fl1~~1'lJrh~elU CME '~mfl
http://www.pidst.or.th
,,::.L=o'j}
911
'l:l'J.Jd
t
~
,~
~1Jd(J'VllJ l<u IlJ ~ltJ'WvHl'iJ1f1f115191~I'lJm'Vl1'W'W
1f1~'iJ1f1f115
lriel~1J 'J(JltJ'W '1 'l!~ ~m'W'lJlll~'Vl6
1l'W'Vl6iJf1 'iJ~
eJf1li:'1''IJ II'l\j el(J1'liwl'W I
Q
.0
{jf1~ ~f11';j ~ ~l~el rlel'Wl ~fl Yl'iJ
1';j tu 1~ ~m1lJ ~ 11tJ'W 'lJ el ~ f11 ';j 1 ~(J1t1a9h'W~
,
,
91
..::t
lJl
tI
.:!:l.
Q.I
~
,
""
q
0
Old
'IJ1~flH'iJ~'Vl11'l1lJf11';j
~.:!:l.
V
"" ""
l'lW11'WlJ'lJ'W
9J
' q """
f1ell'l1If1~
IW~
c::
tI
ff'WltlJ;1el~ 'IJ'Vlm1lJ'W'iJ~i:'1'~11 el'W 1'I111'W'Vl (J 'JIm 1~'I1ff1ml9.l'lJ()~f11';jItJ'W
1 'l!'iJ1f1ml'11191, f1';j ~~" f11J~ rlel'W
1'W';j1~ltl'W ml'l1l91~mm';j
t11f1El1 1,r'l11(J
,
lIJ""
~.I
q
'1"'U'iJ~J;1~J;1~llJfllfl';j~ff';j1~f1';j~~f11'lJ1
~""
"
l~ l~(J '1'"
lJl9lfl~5'IJu5~'Vl1'W(J1l~'1
~
').I
!m~i:'1'51~
"
f1';j~~mJ~flflf1'iJ
1f1tlf1~ llJ;1~ f f1flll?1 'Jw~1'1' 'J(J'I1~f1f11';j fflJ~J;1lJrun'li
"
,
'W'IJ 11 1 'l!J;1 ~ J;1~ () ~1 ~';j 'J~l ~ 'J 1 ~ (J Ill~ () ~ f'IJ tl ';j ~'Vl1'W(J 1 1~ '1
~ elm M
191 ';j 'J'iJ f f1El1 N1J d(J~ ltl 'W '1 'l!ff ~ 1'1''J(J 1~ f11 ';j l~ (J 'J fl'W '!ifj f1'11J;11(J ';j 1(J
~
"
"
JJ'WVif1mf11';j~l~'1 HII'1'91~I'iJ'W~~l'Wd'W 2 ';j1(J ~~'lJmhff'W()';j1(J~1'W
d
9J
,
9J
rI
e:.
N1J'J(J'Vl~ffel~ ItJ'W'IJ'Vll';j(J'Wl'11'Vlf1111'W 1~f11'W~t1~ dlm1~'I1i:'1'll'11l91'lJ()~
d
"
l
0
.o:S
4
,
'1""
"" ""
lIJ"
"'"
'1"~11f11'U
~ lIJ"
'lJ 1~(J'Wf1t1~mml9ll'U'iJ1f1f1';j~~f1'IJ~f1()'W'iJ~
1~19I';j~'iJ~
' "
,
1~ J;1~f11';jI9l';j'J'iJ llJ;1~f11';jff1El1~lll~1Itl'W
';j1£J~ 1Itl'W~I:U(J'WW~ lriflm~ 5511
flfl
~~
0
J;1~f11';j
~
'j}
m~~~'Vl1(J
~
I
IlJ()
.tti
f1~'IJ ltl 'W tI f1~lri()
I
'j/d
Q.I
l~el'Wf1()'W
('W.fl'.2553)
'I1J;1~'iJ1f1~1'U(J'W
~()~I~'W 'Vl1~ ItI~~'I1l~'W';j~'Wmfl'~()(JM1
llJ;1~ Il'1'm 'J'iJ1f1fllN1J'J(J~~~
,
"
mf11';j f1';j ~ ~f1D~ ()~1~1J1f1'11 m(J51(J
"
N1J'J(JI'1''J(J'I1~f1f11';jfflJ~J;1lJtUn'li
"
11'1'1 'If'fi'1 ~~ '1 tim f1 1'W f115 f f1El1
'I'll Mfftf1111m ~i:'1'f1~~Nf11(J'U()~
0
"
1?1'JW ~ ff~l Vl 'D 'WIW~1 fl~ ()'W () () f1 'iJ 1f11'11Il'l1l.l ~ tI f1~
f1~'IJ ~ ~ ,J1'W l~ lJ fftf1
,
"
1
'J1
e:.
0
q
v
,
'1"'U~~'U'W
"" 'jIW1(J1lJ';jf1El1Im~ff51~';j1~f11(J'Ufl~I9I'JW~
~""
,
~
q""d"
1'l11'U1'VllW'J
'Wfl'W'Wf1 l'W~~~'W l~lJlfl ~J1lJf1 llJ;1~ 1~'IJfl() 19I';j'J'iJl~'IJ11f1';j~~f1flel
' "
"
D~ 'I1~~ff1fllf1';j~~f1flm'l!l~~ el1f11';j~~ f1~1'J~~~'W ll\li5~ 'Ill 'I11(J ffU'Vl
l~m~lJlel ~J1lJf1
lW~ 1~'IJflfl ~\91';jd'iJ'W'lJfjf111 f1';j~~f1flelD~'Vlf1flf~
"
"
,
ff1fllf1';j~~f1flfll,r\91H mf11';j~l~'1 ~~~'W'Vlf1flf~ 1~(JlllII'1'1'IJtI';j~
m
'Vl1'W(J11~'1
l'W~
'lll~J1lJf1 lW~ Illl~'IJfl()ll~'J 11~~'iJ1f1Nf1
"
~
ll\91()lf11';j '1"
'U 0'
u'J~fl'';jEl~
u'J~llJ()(J
5~'IJlJ5~ III '111 (J '1 tI flf~'!i'~f'iJ~tlr f1flllm~~~~fl~vr~\91'Wlfl~ 'Wl'J1(J1lJ
3 Illl()
""q ".'
~" d'l'"
ffl9ll'l1U';j~fl()~fl'DI9I'JW~I'U1'Vl
~
Mf'IJfld1lJf'iJ1f1.fJiJi1tJjtJj11m1ru
tI~ I
Q.:f
dQ
... I
."
m'iJ15(J'u';j~i:'1''Vl1i lJru'iJ';j~u51f11T
'I'"~
'Vl f1 el~l~
tI'J~liJ()(J';j~'IJlJltll1~I?1'J tld~;;hEl~mf1 llJ;1~iJI'l!flf'Wn1()flf'WI?1'J ~()
'j/d
d
?lll9Jd
Q.lde:.
NI'U(J'Wlfl(JlJel1f11';jlu'W 'lJliW'IJl~J;1'W111f1~'iJ1f1
~
\91fl 'W D1(J I'l!~ Ill~fj f1lM
, v
~~l11'l1'W~tlf1~
iI''::
H 'I'll 1 ,r~~~ ~ f1';j~~"
f1fl() II J;1~ f1';j ~~ f1
"
lfl';j ~fff1~~1~f11(Jl'l!1~fflJ~J;1'Vlf1ff'J'W 1~(J 'lll~fl~f'IJtl';j~'Vl1'W(J11~'1
m(J'\Hl~
i1 tJj'l11f11';j~el(J1
'"
<Ie:.
').I
,
ff'W '11~ ~fl f1
QI
SI
q"
;:
.d
m~'Vl(JlJf1'iJ~'Wf1t1~mm~lfl'W'1
mel(J11911'W ld';ji:'1' mml9.lfl'W'1
'iJ
<::9.:::S
Q,I
fl1'il11f1'l!fliJ fll?1 'Jlfl~'1if1fl'DW1
j}d
f1';j~~f1'IJ~'Vl11'l1lJfl1f11';j
lIJ 'JJ
I'll
Old
dol
~""d
~llIJ"
""
19I()lJ1~1'U(J'WlJu';j~ff'IJf11';jru'iJ';j~lJ()lf11';jIU'W 1'U'iJ1f1f1';j~~f1'IJ~
do'
19I';j 'J'iJ~115~~ 1fl ';j ~fff 1~~1~f11(J1'1111 'I1l.l~t'W 1~~5~ Illl'li'l~
"
, ""
'W'IJ'J1'IJ';jnru
Inferior Rami of Pelvis
"
'U1~'U'J1mlJ1'Vl1~
mlJf1~I~'IJ llff~~llf1';j~~f1l9f~f1';j 1'W5~ '1~1'li'1~
"
1 'W~ i:'1'~~
,
anterior
llJ;1~
Nl:U(J'W'W(J1(J1lJ f f1Ell
"
Q.I'
lIJ 9J
'I1m(Jflf~ 'UtIl~11,rVl~ 2 flf~ flfl
I91dlfl~'iJ'Wl'lJ~m1'Wl'U1'Vl ~'IJ'IJ'JlJJ;1~ f1~ lJl'iJ'IJ 'Wel'W'Wf1Nfl'W tfff1I'UJ;1~
0'
0'
'~
"" lIJ.1 ""
flf~l!';if1 lriel 8 llrl()'W (lUl'.2545) f1m~~f11'Wfi'Wl'W'I1~~ J;1~ 'I11(Ju'J~i'I';jEJ~
IW~ 'I11(JUd~';j~'IJlJ 1119l1lJfl'W()'Wl~J;1f1IU'WJ;1f1lJ1 'I1';jfl
'Uru~~'Wfl'W'I1~'IJm1'Vl fftf11l\91'Jw~m
'l!ff ~'iJ'W'I1'W 1'J~'W ~()~J;1f1~'Wm
1~'WlJ1f1'1 ~iJmf115mlJ~l~lJfjf1 1'W';j1~19f~f1';j1'Wff1m';j mfl~()'W '1 tim
"
"
,
I
d.o::::o
dt . .
d. c:: 9JcSi lil"
1J~lf1r()~tl1'IJ()lf11fl' IW~ 1Im1~"jI?1'Jw~111f1~'iJ1f1mml9.lfl~I';j lrifl l~ lJmf11';ju'J~'IJd1Jl11~lJ()f1
llJflu';j'IJ1'lJ~f1';j1'W'iJ'W1'U1'Vl
f1 i:'1'f1 'UJ;1~
9J
e:.
QI
d
l:1 ' c::
<j/d
d
lCJ '1J
d
d
d
n
1 Q.I
t
rl()'W'Wel'W5~lll~fl1f11';jN~tlf1~1~'1 'llllfl Illl~'IJflel i1i:'1'm'J~~tlf1~
llJ;1~ i:'1' IJ 1(J1?1'J
ll'IJ'IJ 1 'l!'I1l~ 1
f111'iJ~'I11(J~ 1~(J 1~11'1'1'IJtI';j~'Vl1'W(J11~'1
'lllll ff'IJ<ij~ 191 ';j 'J'iJ 'llllml'11ll'I1l.l ~ f11';j ~~l~el
my
lll'l fftf1tl'J~lri()(J~~l?1d
rl()'W,f'Wlfl(J~mf11';j'l1~~fl~IIJ;1~
v
M1'IJf11';jff1flll'1''J(J
9J
Q
lri() Nl:U(J'W i:'1'lm';j t1N mr~ ~~1?1 'Jl()~ 1,r() ~1 'W a~ (J 1'IJt1~
"
"
'V111,r19f~f1';j1'W'lllD~'iJ'WmlJl~'IJM ';j'JlJnmff1El1I?1dlfl~()~ 5-6 l'W
1'li1lJrul'J'li'iJ'W'I1~~I9I';j ~11J;1~~f115D~fl~,J1~ltl'Wflf~m1'J ~llrrl'U 1,r19l';j ~ '11'1'
{jf1~'W 11'1'11 Hff ~m'iJlf1~'iJ1f1f1';j~~f1D~1';j1fl~W)'WD~I?1'J'iJ'Wf1';j~~f1D~
4
C}
').I
" "
d.<:!:i
QI
'iJ~'W(J1(J1lJ 1'li'l1J;1f1f11';jfflJ~J;1lJruld'li
Q,I
C) 9J
"
";j1£J~
2
,
(J~I9I'Jlel~ l'l1I91HllJ;1~'Wfl'Wl9lel
~~ll'Wi ~'!i1~1T.i'1 1'l!5~ IllJ;1~'iJ~ '1 tllmm'im6tl';j~iY'Vli
lli() 1,rYi1'W
'li'J(Jllm 1~"j115~~f1';j~~f1D~~1~fjf1 \91 ()'Wl'lf'1 1 'l!5~ IllJ;1~ll~lll'l1'W 1'J
~'Wll~ 'J '11 ~~ 'iJ 1f11J ~lfl r () ~tl1 'IJ fl1f11fl' ';j () 'iJ 'W D1(J llJ ~ '1 'l!M~ 'lll J;1~
~~ 1'Vl';ifll~'Vl"'ltltlrf1Ell()1'iJ156tl';j~iY'Vli m'iJ1';j6mlJ11'l!mj()f1';j~~f1 11'1'
l~lJ~'I1~fl5~ ~1:U(J'W~'IJ\91';j'J'iJl?1dW~ l~'IJ11 'l!mj()f1';j~~f1II'1"llll~lJ~
~~'W(J1(J1lJ1 f1El1'l!()iJ() 1,r1'l!1~ ~ 'JlJfl'IJf115 1'lf'Yi1lJrun'lit'W'1 N~J;1~
v
Ml1'W VI ~l :U(J'Wl~() 11 1 'l!9i'W\91 fl'W 'W el 'W 'I1~'IJlln 1d1'Uru~'W fl'W 'I1~'IJ
ltl'WN1J'J(J'I1W~I'Vl(J()ll'J
25 11 1'li()1~111
"
u
,
\91el'Wl'lf'll'W'I1~~ ltJ'Wl'W'I1(J~
, ~lt'W 'Itll~'Wl~(J'J l'Wl9lm~'iJ\91~f1';j
,
v
"
'1 ~'1ifll9l'W
'1"lJm'l1m(Jf1';j~m~ I9Ifl~l'Jf1f1';j~m~\91'W
"
" lIJIlJ'U'W';jt1'iJ1f1191J;11~
,,""
J;1~';jt1~,J1'W ~'WJ;1~JJ'WI~lliel~~f1';j~m~I'li'l~ 'iJ'Wf1';j~lt~ l~lJI~ff'IJ1(J
ltl'W 'H~l'1 fftf1'11'W 1'J'1 f()'W'1 19I()'W f1m~fi'WtI'J~lriel(J\911lJliffll?1'J
" ,
v
Old
"
l'WVI 2
f1m~l'W l~iJI'li' 5~fftf1tl'J~19I1lJl{jfll?1'J lW~lll
~
~
~
el(J1f1fl1'111';j ~fll9lf1W'Wl';jlJltJ'W
el fl f1lJ 1 f1
II J;1 d
'W1511'1i\911lJ'DJ;1
1;1 91.:=1
~
'Uelf1fl';j~
91&
91
~
tfff1'11'W1'J'l 5fl'W'1 l'I1~el
d~ 19I1lJ! iffll?1'J\91 J;1 () ~ fl'W ~ ~ &lJ f'IJ tl5 ~ 'Vll'W (J 1
1'W~ 3 fli;ll-:ll'W 'hjJJ'1oU' riYmJll'llilllJlifD~l'JJlfl~'W riD'Wl'W~1'J
iJ~'Wm~'Wll[j~I1'1~D'W I 'lil~ l~flll'J M\ill:lJtJfl~ Dll~I'J'W lriDflJtJ~~'\'ll'W
oU'lll'1:lJ~~ 'WDlilfllU'Wl~:lJ~'loU' tJl\illillmifD~l~'WllH~'W 1'Wl'Wli
flJtJ~~'\'ll'WI'Jl'Wl~lICJilill:lJD[j~m~D~Iil[jD\il,f~flm~l'Wll[j~flm~fi'W2 l~\il
'ihl:lJ~ ~1:lJ
'1fl 6
1~\il;1'W
8
,
Dll~I'J'W:lJlfl 'hjm'JJl~(;1flJtJ~~'\'ll'Wl'Jlln~lICJilill:lJD[j M 1'W~l~ml~I'J'W
iJ~'WD~:lJtflll'i''JJlfl'WDfld~
IilD'W flm~fi'W~ IoU' tJl\illriDI'J
~
&~I
~'Wm ~ 1~:lJ:lJ~l'llll'l~l[jfl'l 'U'W'\'ld~l~flll'J
dod
'"
""
"
'
~I
d
1'1ru'WDCJi~lu'Wfl:lJlJlll~'\'l1'J
5 IilD'Wl'll'l
1'W'\'l
I
V
I
,
,
"lAIAld
<I
luu~flfjl
~'JJlm'W'\'l61'i'11'Jr'1'W ll[j~1:'I'~rrl'Jr'1'W11 ~fl1:'l'nil~I~'W "loU'ti1D\ilDDfl"
1'li'W
m~~fll~"lml'W loU'~t"l\1"l
1'W~1~~flWelfll1:'l'lJlnl'lm~'illl'J'ltJ,t1
v
,
"'l ," "" """
c::
lfJliJ9J1
~ "l~l"l'l
ItJh~'Wl'Jllllm,,1'J
CSC
9J~
c:;:
tr~I~l1J~I'WI'J~'Ii"D\ilifl'lif1J'l'1l
'Ii[jDl'lifl'liflJ CSC
1"
~c:;
r.!:i
mlJlm\ilWD\illillfl'il~ 'Ii
fll~l'Jf1fn~m~mrfl 'il'WoU'D~DiJ\il ll"~ 1:'I'~I'WfliJ\il ~~~\il~'W'l'iJfflfJl
lllJlJ'li1:1f1f1lJ1:1':lJ~[j:lJrun'll'ltJfiD'W 'li1:1~fll~fflfJl loU'[j\il[j~ mfll~
-J
.d
~ d
\l]'
tJl\ill:lJDl'Jlill:lJI'W Dlil lfll ~ :lJl1l1'J !tJ
Q.I
m!llill1:1'\il~'W~'W ~~'li11~thtJ
c::::
'j)
'J}4
1:'I'D~ m~ 'il fll'li'W'Ii'W llill1D~
QI
Jl'liUfl"\il[j~ 'illfll~:lJ
5 1'W
I
t 1:'I'fldl
52 nhflf:lJ
l'Y!~D 48 nhflf:lJ
'"
'"
"l "AI
.flltJ'Ii"~fll~~flfJl !l'llJ~~'JJlru
,;, "
!:lJ~
1'Wl'W'\'l
'" ""
"l"
,
~ ~ '\'l1'W D1'Y!l ~ 1~:lJ rr ~ Ifl Iill ~ 'W 11 ~ \illl\il ~ l~ fl'l ~ ~'W \ill:lJ
~l~fllI'JJ'W'ill~[j~ fi'WJ'W~lll~"loU' 11l~mfll~tJl\illill:lJlifD~lafl mfll~
DI'Jl fl f lJ tJ
fl1:1lJ~tJfl~1'Wl'W~
6
"
5
"l "
"l"
lill':iOl
r.1
c::
9J
o'lfJ 9J
Ii 9J
~ l'U tJ 'W 1 1'11 'U D'litJ ~ ~ ll'l 'W 1'Ii II 'W '\'l1'J ~ \il Iil ~ ~ 'Ii 'W flll [j ~ oW ~ 1'1 'W 1'U
9J
d
r1111
m~l'lfliJl'l 'Ii'JJll'Jii~ fll~ l1'1~D'WDDfl'illflI'111l'Y!U ~tJfl~lV)tJ"ll~m!DI'J
QI' ~
r.!:i
c::
'jJQo
9J
tll'il:lJN[j 1'li1tJ fl\il'\'llJ'\'lD'Wll'Y!"D"lI[jfl'l 1111 mfl\ilfll~1Jd:lJ l\il
d.
'U
J' c::::
9J
9J
r
11m~~fllJ\il'll''W\il'WltJ'W dislocation m'l'll'flll1 subluxation 'Wl'il~
0
<::l.'::::"
,
'" "l "A I
",.:,,,,, 0
I'JDmlJ !\il u~~llil'\'l'\'ll
1"""
.:,
.:,
'Ii:lJm~~fllJlil1:1'l'JJl~(;1lfl\il
I
v
1
""
!\il'\'l"l 'W'\Jru~'WD'W'Ii~D
"l" '"
'\Jru~~'W fll~ 'W D'Wl!~ ~'WI~'W ~"l~ fll~ 11'1 ~ tl'W I 'Ii 1 1'W vil~ 11ll'Y!'JJl~1:1':lJ
1:'I'1:lJ1 mVll Mlnl'lm~\ilfliJl'lll'i'1'li'W fll~'l1floU'tl~m~'WtJ~~~l'v1l1,rm~\ilfl
~
oU'D~DfiD
Carpal bones
~
9J
~
l1'1~D'WDDfl'illfl~m'ilfl~lll'i'm~~flltJ'W~'li1:1"l~tl
.c.
0
Q.I
nmfl~~\ilfl'\JD:lJD'il~I9l\il'U\ill11
l.rJ
1l.rJ 91-d
1"'l
""
'AI':'
"l1:'l'51"l~1"lfllI'J1,r~ fll~~1il14D~lJD~
dengue hemorhagic
mru Traveler fever '
"
~I "l"
flDl'illlJ'W!\il
fever
1'Wl'1lJll~lJ11~tJltJ~lJloU''li1:1''lfll~I~'W
'\'l1~ll'W'\'l6JJfl.wflii"l1:1'1l'Y!\?l111nlil'illfll ~1'1~\il~D'illflDll1l~ 'lijD m~Vlfj
:lJD"loU'l:lJl~D"l~~I~'W'\'l1~mDfll1:'l'm~~fliJ\ilDDfl'illfl~M
'1'11 1 ,rlnlilfll~tlfll1:1'lJlW~I~'W 1oU'I9l1:lJ'JJl ~~I~'WtJ~~I~'W~I'1D"l.wflii~I~:lJ
'lijD ll:lJ[j"l
1~:lJ1'Wfll~iu'ilnI'JIWfl h1'1 Traveler fever 1Pi'1tJ l\iltJl'U'Wl~~'JJl~II'W'\'l6
~I'1D"l\illl[j l~fl~~ I oU''Ii~''l fll~ 1~'W'\'ll"lltJvi D"lI~tJlr'1lJ -WDllllN'tJflfl1 D"l
'lijD I tJ-nf1''Wftflfjl'Y!jDloU'l~ltJr'1lJl~D'-l'l lW~f)ru 1'1t~h "l1~tJ'W
~
~
tJ~~I~'Wiflr'1l1JfiD
fll~I9l~1'iliu'ilnl'Jll,,~fflfjll1'1Hft51~
~l~flltJ~iJlilltfl'Jl 1 ,rloU'l~ 11l1'lil~D"ll'Jlflln'W fl111l1~'\'l6'il~I~ I'J'W [Nml'W IIPi'
lV)I'J~I'1D"lf1l~nm1'Wfll~NmJ'W-nf1fj~ IPi'D"lI~'W~~I~tJ1:'I'''~ lW~ ~,f"l
f111:1 ~ flll'J~ II ~ ~ll ~ ~IW~ f111:1"l 1'il ~loU':lJll ~"l~'W rH
0111 'V'l '\'l61oU'l 1'illl [j~
'il~1:'I'1:lJ l~ i:I "\ilfll~ 1i'l'Jlll [j~fll~ 191 ~ l'il'\'ll~,rD"l
tJBtr~fll~""l tJ~~'liiJ\il~ltJ~ltJ'lij D~lJtJ~~:lJlru IIPi'
I
1:1'~lJ
A
""
0
".'1
:lJfll~'W1W'WD~lJ11'J
2
~11'J
d
~I
CJi"lllJ'W
~"
.:,
!'U'illflm~~f1lJ\il
lriD f flfj llPi'ltJ'Ii 1:1fl fll~ ft:lJ~" :lJrun'li I'll 1'Ii"! oU'll"~ Dlfll ~ I'i l"l'l 'IiltJ I tJ
~
m~'illfl
.fll'Wf"l~M"l:lJD"l11l1~'W ~"lJ'Wrr[jtJll'W'\'l6DD{[ 'li1J~mYirfllllI'JD:lJflJ
1
dengue fever
",
".'1 1 I'J 'il ~ ~"d
'"
" 'W 'il [j ""
NlJ
1:1'fl 1:1'\il 'll''Wll''
~ ftllll'J fld'11
fll~ "
'll'1'J 1[j \il "l"
!'U 'Ii ""~ DtJ 1 \ill
, 'll''W
9J
0
2
1:1':lJJ.,j~~l'WliI'1D~~Dfll~Vl\1'il,.r~D I tJ
Q.I
l,r'JJlfl~'W l~tll,rftl:lJl) (;1iu \JneJ 1 ~flll,,~fflfjll ~flllPi'~:lJlfl~'W ~~li
"
01 'llllll'l 1m
ft'W 1'ilN fl-n flfj~l 'Ii~l'W
d
1'W~l~fll~ !'Y!mltJ'W\il'U'W:lJfll~lfllJfldl\il
,
'" , ~I
'limtJ'\'l1'WD1'il'il~I'll'Dl11lJ'Wl'W~1~
v
.:,
c::::
!'\J'il~[j\ilD~llm !:lJ'Wl'il~ !'U[j\ill'W~1~ ~fl1"l1:'l'~1"l~1"lflll'J~flllfl!'U1'1'W\1Ufll9l
.,: "d .:,
1~:lJt1:'l'fl'lilll[j~
3-4 'lil
,
d..Jd.
d
1Pi'11'J19l'WlD~11 'il~'lilili~ll[jfflfjl~llD"lIIPi'D~l"lh ifl'lifmll'J~
"l"
!'\J[j\il
Serology "lll~
~1~I'J'Wrr~lfllill~'Wlm~1:1'51~~1~flll'J~iJ\illtfI'J1'illfl
" ,
\l]
fmI'111U'Wl~1'1 1'W~11'J~ I 1'1f"l£!\ilYlltJ 1~'WloU'D~ 5-6 1'W
~ 1111'lil'W ~ l~ln\il 'illfll4tl 'l If1:'I'tl~1"lI~tJllft:lJDI tJ '1'11 1,r~ tJ lCJl~ tJ'W r
ll[j~ 1il~1'ilfflmD~1~1fltl~\il llil~I'J:lJI'ill~I~D\ilIil~l'il CSC ll"~
~1
""
DDfll tJVll 1,rfll1elfll1:'l'lJl1ltJ I tJ
~I
Dl'il~fl~l'WflmtJllJ'W
Iil~ 'il~mm
ll"~
'"
~I 0
llJ'W'ill'Wl'W'JJlfl
!1'l1'J :lJI9lD"llJl'liD !~1'1I:lJDm~~fll'Ul\11:1':lJ~[jmfll~\ill"l'l
ll~Olf1\il 1m,j:lJfl1:1lJ
d~
c::
9J
flm:lJl'WD 11:1''WlD'W
l'\j-DlfjD~l~'lYl~fmiJl'lf"l~~01iJl'l'limI'J1'111l'Y!U"l'lijD m~~fl~'W1myiJ\il
Oll'WliiJ~f lJtJ~ ~'\'l1'W D~ '11 11l11'i'I'1D~'W1I tJl ~ ~'Wl'Jllll[jI~Dhhfllfl~D
Serology for DHF '\'l1ll'W
,J
9J
19l1ll'li'W~'\JDI9lD
,
'il"l'Y!ltJ !tJ !\ilDtJl"l~l\ill~l
l'WYl 4 flm~l'W riD'Wl'W~1'J l'Y!~DDDfl:lJlfl ltiDDll1l~ ll[j~
DDfl'JJll'liW)'W
v
d
"
,g;,
o
(Process of Inflammation) ru
~
~Dlfll~'limtJD~1"l~Ill~'\'l6cil'W 1mYJJfl11l1ci1\J lW~1Jl~1'1f~riYfl111~'W
subjective
1
.:,.:, '"
0
"A I
"
~1
"l "
!:lJ1:1'l:lJl~(;1'Wl:lJl 'll'lJ~~ !1'J'll''W 'Wfll~l'W'il'UI'J!\il
"l '
~"
ll'W'\'lI'JI9lD"l
[j~la tJ~ 1ci'l'il ll[j~fl'".n ftflfJli'lil:lJ run'lil ~:lJl~:lJ 'il ~'lill'Jl ~:lJf) ru ~ 1
(value added)
'il~vll1,rloU'l1'il m:lJl~i:liU'ilntJll[jdflfJl
hf1 M:lJlf1~'W
il1'1~ l~,.,jDlfll~~l)l.wfl111'1'W I oU'tJ'Wl'W~l~I1'1~ 1'J\il (anxiety)
lltllll'W '\'l6tT'WlD "l~I1'1 ~ tJ\il I'W ~ l~ ilm 1~,.,j11l1~'W ~ 1"l'Y!l fl
fldl:lJ'ilj ~
D1fll ~ ~
fl'W '1 oU'tJ'WlJfllllm'W1'11~1
t::\
limitation of movement :lJ
!:lJ !\il:lJ
mfll~l~lJtJl\il lltlliJ"l~N[j~"lf"l"ltJii"lm~~flflD ~N[j~m~D"lltJii"l
'1
fl~ !'Ii[jflll"~
brain circulation
?I
Q.I
,J
I
d
Q.I
rI
r
llJ'W19l1DI'J1"l'li'W"l'UD"l1:1''il'li~~:lJ'\'l11 :lJ'4fjl'J
I.
1~'Wl1fl.u1 'W l1fl~jtJllJi:I ~"l~'W~~l~'\'l'liD"lr1"llPi'l9lf1:'l'H
Last Editorial Review: 3/2/2010 by Charles Davis, MD., PhD;
"l1:'l'51"l~1~flll'J~iJ\illtfI'J1
1~'Wml'Y!\?liflr'1l1J~Vll1 ,rln\illoU'llPi'
v
1iJ .... I
9J
1""" '",
~ I'l fllJ I'l 'il ~ llJ fllill 1:1''W 'W 1l'Y! [j D"l 'Ii ~ tll1:1''Wl1,'!el \il \ill '\'ll 'Ii:lJ fll ~ 1'1 ~
Kelly A Ellis, MD Department of Emergency Medicine, Univer­
1m
I'W ~ l~ m
•
o
9J
<::l.
~
r-:t
~
'\JD"l'Wll'Y![jD"lIl[l~I[jD\il
0
r.!:i
r.!:i
1 9J v 9J
'\'ll 'li19l1~D'W'\J'W!1'l
0
'jJQ.I
d
l.rJ
r-!
0
C!
.:::::.
'Ii~D
http://emedicine. medscape.com/anic lei 166320-overv iew.
0
d.
QI
lfl\il:lJfll~Dfll1:'l'lJ
sity of Maryland.
2.
llJ1:'I'1~:lJrun'll' lJ~
I
'UtrlJ~
I
'Wt]fjm1'1:lJ-~"l'lil1'1:lJ
255 I.
f)nftillllmnlll(;H)VlK£Jllll~fH;l'lh:lI~£J'l'IHl'l[Jl oseltamivir 11l~£JU
l'U~ihm~il'<U'I11Vll'11qjem,j~lil'jl 12 l~eJ'U
1-n£JUnU adamantanes
1~'WI'Jll'Wfl~:JJ neuraminidase inhibitor
Oseltamivir
~
'j1J adamantanes [28 'j lV (16%)
'19J~
?lJ1J amantadine]
fll'jftmn1?llJfll'jMI'Jll'W11\j'Vl?lmJ'HJl~ 7 1'W 'lJ'Wl?l 1,000 :JJfl./flfl./
d
0-2 I?lV'W, 3-5 I\i1V'W, 6-8 I?lV'W
ll'(l~
2.2
~
?l'j1J rimantadine, 37 J lV (20%)
, ~
1'll:JJ1W~l'W'UV~'U'Wl\i1lJl oseltamivir
-ti.
.:!:!,
'illfl
'19J~
IW~
d '
'l
9J.'1
'Wl';!u1VVl~
Q.I
9-12 I\i1V'W l'Vllfl1J 2,08, 2, 2,04,
:JJfl./flfl,jr'#~ I91l:JJci'lI'l1J 'IJ'Wl?lVl~~,,!?l~~tJ1Vil'1'f1J
7 :JJfl./
f1#~ (250 I'Vil'lJtl~'lJ'Wl?llJl~l'1fl'Wl~ fli:J'il~'1J'W) 'W'lr;h~vhJl'ltl'j~1J1J
11 'j ~ m'Vl ff1'W flm~ll(;l~~ l1UlirlJ;ll91 ~ l 'W 1'W:JJlfl 'hJ'W1J1Jrul1ld'l'W 11'W
'l'WfllJf1JlJl oseltamivir
d
J
')"~QI
eft!
'Vltll~:JJlfl'lJUlI(;l~l1\j~1911191:JJ1lJ 'lJtll~'Wtl~f1fll'jtlll1UII(;l~lJl 'l.h~I'Vlfl'
'W1J~tJ1V l JlV'l'Wfl~:JJtll~ 9-12 I~V'W~Vll~V'W~:JJ'W'W,rt11JfllJf1J
'(mf~tll:JJ~flltll{JJ&ll'1f'l~ oseltamivir 'l'W fll'jfmlllwdjtl~t1'W hfl
•1
u
~
l.u111?l111qJ'l 'Wl~fltll~
~
11~'W 1iJ l?llJ~fll'j fYmn'W1Jllfll'j MlJlif
1~'Wnm 5 i'W l'Wl~fltlllJ 1-12 11 ~~&l?ll~tl H111?l111qJ 'lh V'I'll 'l'lf
'j ~ V~l 1(;l l 'l'W fll 'j II 'W 'i I~tlll(;l~ fl l 'j I~ 1JtJ 1lJ(;l?l (;l ~tld l ~~ UlJ 1:Yl f1t1Jll (;l~
I
~,~
.1
u(;ltl?liW
d
'" ~
.'1
9J
1'll:JJ1W~l'W'lJtl~'j~lJ~nml'il1Ju1(Jll(;l~:JJ ~'lJ(;l?l'(l~
i1 1m ~'1J&lfll'jru'lJtl~1;1i'Wflm~Vfll'ff1J'(l?l(;l~ftllJ(;l~44
9J
~
0
'll1lJll'!'(ltlfl (placebo) 'ffll1'j1J
t1~ 1 (;It! tl ~m l:JJiJ '(ltl?l.f1V'lJ tl ~lJl
9
d
9J
,
tllfll'j 'j, 'Wll'j ~
d
'"
II:JJlJ~:JJml:JJ
I u
d
11'j tl:JJml:JJI'ffV~11
m'l'n~'l'Wmru~~
I 11
~
d
9J~
1'W LJ 'j ~l 'Vlf('ffl1f~tll:JJ ~ fll~ fll'j l'1fvld'
'l'WflufmnNtJ1v'1.u111?llm,utllvUtlVflll
u
,
do
25
l¥ilJ1Jt11Jfll'j
-:;'1
~'WI?lfltll~'WtllJml
IW~
36
'j)
d
'il~:JJ i1l1~11 'Vl 'j fl'll'tl'W
d
Q.I
'j)
d
'il ~V~:JJ'Utl:JJ '(l
~
d
3J
..<!.i.
flfl./m~ 11J'Wl';!tJ1V'l'Wfl~:JJVl~ 0-2 I\i1V'W 1'll:JJ1W~l'W'lJV~'j~v~nm
UJ~'Vll'WVl
I
I
ll(;l~
9J.'1
adamantanes 5
~
IfJ
1'W~~
,
"'~ 9J~
oseltamivir l';!u1V'Vl
~
Q.I
~?l'j1JVl
I
oseltamivir
dlll
2
fl~:JJ
(p 0,51)
.
~
'"
~
lJ1;1'l1'Wflm~Vfll'ff1J
'j)11I
,
d
I91lVfll'ff1J 'Wl1;Jfl ~11'(l 'WVlJmlfl~:JJ'Vl \i1'j1JVl adamantanes VVl~:JJ
I
UV1:Ylf1t1J (1 ,7% ll'(l~ 15.4%, P <0,0 I) 'W1Jml:JJN?lllfl&l'UV~J~1J1J
'l.h~'ffl'Vl'l'Wfl~lJll'1'f1JlJl oseltamivir 19 JlV (16,5%) ll'(l~ adamantanes
17 JlV (26,2%), P 0,13 l?lv'W1J irritable fl~:JJ'(l~ 13 JlV 'W1J~tJ1lJi'fl
1\i1v'1:iJ~m~'W,rt11Jfll'jll'1'f1JVl3 JllJ JlV~
I il'1'f1JflU1U'ilQViVflJ'W
'i1:JJt11J i.u111\i1 hI qJ 'l1U?l A ~VlfllHl~lVi'fl'Utll~ il'1'f1JVl amantadine
1~'W1'W~ 2 JlV~
JlV~
3
2
1~:JJi'f)fiv'Wd:JJfllJfmnI'1'1v
1~'W~tJ1V~il'1'f1JlJl
amantadine
oeltamivir 5
i1 1:JJ~
1\i1I'J~LJJ~1&llflVi'fl:JJlriV'W
rm:JJN?liJfl&l'Utl~J~1J1Jt'W'1 i:iJlll91fll'll~t1'WJ~l1ll~
2
fl~:JJ 'W1J~tJ1V
1'W'UV~fllJI~:JJfmnl'Wfl~:JJ~Mf1J oseltamivir
~l'Wml:JJLJ'(ltl?l.f1lJ'lJtl~Vll'Wl~fltll~ <I 11 'hJ:JJlflUfl ~1V1v~ I 'jlV~l'W
lirV;ll91i1lV'l'W 30
'illflfll'jftmJlIl1J1J~tl'Wm)~'lUl~fl~~'W
I 'jllJ ~tJ11'J~llJ~1&l failure to thrive IW~ interstitial lung disease
103 'jlV
tll~m~1'J
'1l'1'f1JlJl oseltamivir 4 :JJfl./flfl,J1'W 'Wl'W 3,9 1'W 'W1Jll
7,5
l~tl'W
l:iJ~:JJ'w'W,r
•
tld ritl'Wll~1
~
IW~lirl'J;ll91l,iV ~ 'ill fl h
f1LJ tl?l~ Vl fll n , 'Wll HIJ lfl~'W
t11JfllJ lirl'J;lI91IW~ encephalopathy 'Utlldl National Institute of
Allergy and Infectious Diseases (NIAID) Collaborative Antiviral
Study Group (CASG)
ClQJ~ldHVllfll'jftmnll1J1J'lLJ.ul~l1Ull~V1
ti1Jlfl~'l1'il'(l'Wf(l'ffI91{Il(;l~f11l:JJiJm)\i1.f1I'J'Utl~fllJ
'l'lf
tll~Utll'Jflll
2
oseltami vir 'l 'Wl~ fl
11n:JJ1f~'l'W'V1lJfllIJflln\i1
Kimberlin OW
eJ.f1ll~l£J: fllJfmn~tJ1lJl.u111\i1'll1qJ CJl~UCll'Jflll 12 l~tl'W 1'1'1lJ
oseltamivir
~ml:JJllm)\i1.f1lJ l~1JN'(1.ul~l~lJ~l'lc)J~1J1JiJJ~'ffl'VlIl(;l~
'ff:JJ tl~ '1:iJ 11191 fll'l l~ 'illflflU f mnl'1'11'J adamantanes 1 \i11'J'W1J1;1i'W flm~
Vfll'ff1J I91lVfll'ff1J JlJ,jfl il1'(1
11'(l~f1tll~ ~
University of Alabama
UClI'Jflllfl~:JJ~'ll'1'f'lJl'Jl
adamantanes
tldl~iiUI'J1:Ylf1t1J
'ffl1f~tll:JJ!fll i1lI'JM NIAID CASG il'1'vllfllJftmmlfln'l1J~ltil'J'W
'Utl~~tJ1(Jl~fl&l?lI~tll.u111\i1'll1qJ CJl~Utll'Jflll
,
do
,
IV
QI
d
if
a'
'Vl:JJlJ1JfllJJflfll'VlY;)''Wl'Jfllm'W11lJ
f1,f(. 2006
I
15
1111~
~l'W1'W
I 11
180 Jll'J
mil: Kimberlin OW, Shalabi M, Abzug MJ, et aL Safety of oseltamivir
2000 ­
compared with the adamantanes in children less than 12 months of
I
'j~111l~
f1.f(,
~tJll'J 115 Jll'J (64%) il'1'f1J oseltamivir, 65 Jll'J (36%) Mage, Pediatr Infect Dis J 20 I0;29: 195-8.
~
QJ
'j~~1JmVlH!~'Il0'lm
'1
V_'I
d
~.d
I'j.H;jUl£.J1~f)V1~I'lf0
lopinavir
~
.0::1\1) 'VQ..I
HIV 'YI 1~'j1Jm
mr.:J'il1fHtJ~CJ'WJJll~'WCJ1miTtJ!'W1'Wlfl'W
l'i''k!ll1J1Jlmtl1Jlfitl1Jf)1Jtll~laJty
:::1
d
I
~
d'l" ,
'li1Jtl(Jll(l~JJ
Lopinavir/ritonavir (LPY/r) lu'W(J1'Yl
a'
91
g/ev
?I
fHu'W(J1
,J
\?l'J111fl'l 'l'Wf)~JJ protease inhibitor (PI) 1~1l'W'Yl(J'l'lf1flfJlf;j,JW\?l\?lI'litJ
Q.I
d 9J
I
JOt.
gJ
IV
2 'flf.:J tltJ mr.:J'il1flNtJ'JCJ1~f'IJCJ1vi''W1l'IJ'IJ'W1Wfl'W
4 £Y'tJ\?llrf
4 J;ltJ\?llrfll~~
I\?lCJ1~~'IJCJ11 'W fln
fflEJ1 h'fl >4 lJfl./~. ~tJ'JCJiJ~liT'IiCJ~l'W (interquartile range. IQR)
'1JtJ.:JtJ1~
tJ
12.3 (10.9-13.4)
')
J1'l1tJfl 32.0 (25.5-39.5) flfl.
,f'W~~h
iI~11
lW~
HIY 'Yl(lJJl'I1(l'J'il1flfll11flEJ1WWCJ1'!\?l1 non-nucleoside reverse
f1lCJ 1.1 (1.0-1.3) lJ-
transcriptase inhibitor-based highly active antiretroviral therapy (NNRTI
(65%) lW::; 45 11CJ (83%) iJ HIY RNA <50 lW~ <400 copies/lJ~. ~1
based HAART) fIl(JM Thai National AIDS Program (NAP) ll~
iT'liCJ~l'W (IQR) '1JtJ.:J'1J'W1\?lCJl LPY '1Jt\!~!vi'f1JCJ1vi''W1l1J1Jll(l~CJ1'ff1iTtJ!
l~lJCJ1
'IJ~,r'Yl
255 (230-289) ll(l::; 282 (247-299) lJf1./lJ /f1f.:J ~liT'IiCJ~l'W (IQR)
~.:JmlJ11t1'lMCJ1'l'W'1J'Wl\?lmJJl~
'1JtJ.:J 1::;(J::;l'J ~ 11::; '11 'J1.:J I \?l11J CJ1 \?l 'Wll'IJ 1Jll (l~ CJ1 'ff1lJ tJ! 'fl1.:J i!\?l 'Yl1CJtI.:J 'Ut\!::;
LPY/r
~'l'lf'fflfJl'l'Wlm.:Jf1l11~'WCJ1vi''W1l1J1J
Abbot, soft-gel capsule 133/33 lJfl.)
'fflJ 'Ml\?lCJ 'hivi'tJ.:JI'1\?l1l'!J.:Jl~\?lCJ1
(Kaletra,
~tJlJ1l~tJ.:J'il1fl.:J'lJtJ1~JJlt\!iJ~ln\?l
1m .:Jf1l1~.:J'MltJ~CJ'WCJ1l~'WCJ1'ff1iTtJ! (Nii\?lI\?lCJ'IJ~,r'Yl Matrix,
Q.I
'fl~ .:Jl~\?lI~tJ 'lMlvi'f'IJCJ1 'l'W '1J'W l\?l~mJJl~'fflJ
fYflfJlltJ~CJ'IJlYiCJm::;~'IJCJ1
u
B'Wl~CJ,
4
Q
9J}1
d i d \;1 'J}Q.I
d Cj)
I
9J'.:J'il~JJf;ju'JCJl\?lfl'ff'J'W'I1'W.:J \?l11J(J1'Yl\?ltJ.:J\?l\?lllm
tablet 200/50 lJfl.)
lW~(J1'ff1iTW
'Yl1.:J
'1J t\!~dcJ.:J llJiJ'li'tJ1;j(lf1l1
'l'W~tJ'JCJ1~fl~1vi'f'IJCJ1 LPY/r vi''Wll'IJ'IJ
LPY
1'JlJ~.:JNtJ'JCJ~ lvi'f'IJCJ1'Yl\?l1l'Yl'W ci'J'W'I1~.:J~.:J
lJ1f1tJ'W
~
~ll~'Wvi'tJ.:J lvi'f'IJCJ1~vi'tJ.:JI'1\?l1l'!J.:J'fl~ .:Jl~\?l':hiJN(l~tJ1 ::;~'IJCJ1
CD4% 22.5 (20.0-28.5) % f;ju'JCJ 35 11CJ
~
2
lit
I
l'il1~1~tJ\?l
~
9J
<j}Q.I
Q.I
ll~::;
12.8 (12.0-13.6)
"'"
12.4 (11.8-13.4) i''Jl:lJ.:J
Q.I
'W1J~1
lrough
<j}
Q.I
1l\?lfl~Nn'WtJV1.:J'bjiJtJCJ~Y1f1tJ! [7.3 (4.4-9.8) lW~ 6.7 (5.0-9.9)
lJfl./~., P 0.86] I\?lCJiJ~1£Y'lJtJ1~-ff'Ylt'1Jtl.:Jm1lJN'WutJ1 64% U~~
o
Q.I
9J~rl
.J
e:v
d
\?lllJm\?l1J 'W1Jf;ju'JCJ 13 11CJ 9J'.:Jm::;\?l1JCJl LPY >10 lJfl./(l.
49%
'1Jt\!~
ll"\?l
f1JCJ1miTtJ! 2 l~\?l/'flf.:J iJllCJ'Wfi1EJ~lW~tJll~CJ'W I\?lCJtJ1f1l1'111CJltJ
.:t
d.1:
1 d
9J
1:lJtJ(l\?l'U'W1\?lCJ1ltJ'Wm.:J(l~ 1"21JJ\?l f;jtJ'J(J 23 11CJ (43%) lW~ 27 11CJ
(51 %) iJ cholesterol ll~~ triglyceride lfl'W 200 lJfl./\?l~. I\?lCJlti
Q.I
4'.Q.
d
ll~::;'flt\!::;
'WtJ!. 'Ii'WCJ'J1 J,]'Ii'Wfl'il
14tJ HIY
tll~UtJCJfl11
18
lIJ
91
gJ,"1
.r::9
0
C::::.e.
Q.I
1\?l'Yl1f1l1fl'flfJlf;ju'JCJl\?lfl\?l\?l
tJ ~.:J !vi'f'IJCJ1,!m
QJ
rlQJ
d
Q.I
'ff:lJ'W'W'lifl1Jf1l1m~\?l1JCJ1 LPY
>10
lJfl./~.
'WCJ1'lJl~
.e..:i
I.c::.
lW~ 'fftll'IJ'W i!'1JfIl'Wl\?l fHl'I1.:J'li1\?llJ 'I1l11'li'W
lJt:)'W1(J'W--ff.:J'I11'fllJ f1.fl'. 2008
~
I
1::;'I1'J1.:Jl\?l tJ'W
I\?lCJf1\?lI~tJflm'W1~~tJ'JCJ~.:Jlvi'f'IJCJ1 LPY/
~
~
r '1J'W1\?l 230-300 lJfl./lJ /f1f.:J '1JtJ.:J(J1 LPY 1'W(l~ 2 'flf.:J 'W1Wfl'W 4
2
"~,,
1'W1::;CJ::;mfllJf;ju'JCJ '1 m'IJCJ1\?l'WII'IJ'IJ
42 'fl'W
" 9
(p >0.05)
LPY/r based HAART
tl.fhhltl: f1l1fflEJ1~tJ'JCJ1~fl~\?l14tJ
c::::
Q.I
'ffu\?ll'l1
d
I
LPY
'I1~tl'hi
~. 1
9J
'1 9J
'1Jt\!~ \?l11JCJ1\?l'W1l1J1Jll~~CJ1'ff1lJtJ!
~
lJ'liCJ'il1'W (IQR) 'UtJ.:J C
Q.I
"" ".'1
~
i
".'1
~
0
I\?lCJf;ju'J(J'W1'l1'Wfl
HAART I\?lCJf1l1'lMeJlmiTtJ! LPY/r
~'JCJCJ1,!m LPY/r based
'\J'Wl\?l\?lllJ'lh.:JJl'l1tJfl'UtJ.:J~tJ'J(J
HIY
1\?l(JiJ~tJ'JCJl~flci'J'W'I1~.:J!vi'f'IJ(J1~vi'tJ.:JI'1\?l1l'!J.:J'fl~.:Jl~\?l1'~1J111~~'IJCJ1LPY
'l'W'Wm'fflJ1'UtJ.:JNtJ'JCJ~1~f1JCJlmiTwtJv'l'W1::;~'IJ~Hl'Wf1l1fflEJ111'fl
u
~
~
!vi'
'ltill\?lfl~l.:J 'il1flCJlvi''WI11J1J lw~iJfln m~'il1(J'UtJ.:J1~~1JCJll 'Wl~tJ\?l'1JtJ.:J~
18-35 flfl. lvi'f'IJCJ1 2 llfltJ'll(l ll~::; >35 flfl. lvi'f'IJCJ1 3 llfltJ'll(l 1'W(l~
tJ 'JV~ lf1'11 'lMCJ1vi'Wl1J1J
~tJJJll~ltJ~CJW~'t-W1'ff1iTtJ! I\?lCJiJ~tJ'JCJ~I'li'llf1t\!c0' f1l1fYflfJl
l~lJ~m'JlJl~'W 54 f1'W ~tJ'J(JJ1'l1tJfl 15-25 flfl.'l~f'IJCJ1 I l~\?l
'illf):
2 'flf.:J
~
1JI 'j)cv
Q.I
I
d
'W1'l1'Wfl 25-35 flfl. 1\?l1'IJCJ1 1"2 l1J\?l
ll~::;
~
Q.I
lIJ
'J}Q.I
Puthanakit T, Chokephaibulkit K, Suntarattiwong P, et al.
'W1'l1'Wfl >35 flfl. 1\?l1'IJCJ1
d
~ d gJ
dllJ j}Q.I
~
1 d
2 llJ\?l 'J'W(l~ 2 m.:J lJf;jtJ'JCJ 21 11(J (38.9%) 'Yl 1\?l1'IJCJ1m.:J(l~ 1"21JJ\?l
Therapeutic drug monitoring of lopinavir in human immunoclefi­
ciency virus-infected children receiving adult tablets. Pediatr Infect
\?l1'J'ill\?l1::;~'IJCJ1~1'ff\?l 'l'W9i~lJ
Dis J 2010;29:79-82.
I
Q.I
(LPY trough plasma concentration, C
q
1~1~1
)
aJ'CV"",.o::t
Happy Birthday
fl'U~f)f>I~~
1
I
f>I~
~-:jtGi3J~113J3jiiiGlii11(;Nluflla~3Jlfl'ifu
,
uGiflthtGi3J~lU1UtJ~3Jlfl'ifU(;NluiiiGl
ttlu..nh~"ll f1-:j t';il~~~'W~l";~u~ut~h1~
13J1"lfl'lt!1~"llfl-:j ~u~u~~~'th ~113J t"li'11~1u~-:j~ t';il'W~
~
~
Th£! TJ'£!fJ1JJJ£!JJ1 uf C'UJJJJJJJJJJi1y .IJtljJJiJ'£!d
R£!spinJiuJ'Y 11'£Jt11JJjEt1iuJJ:r!:
h Idr
bd
4-40
eiqh
or 5-8 mg/kg/day
roxithromycin
Good Clinical Response in upper & lower
respiratory tract infection and skin infection 1,3,4
Convenience1,2 BID Dose, Small tablet easy to swallow
Low side effect 1,3,4
*caused by organism!' sensilivc 10 roxithromycin
~~~~i'\\:M1~~ce. Suppl55 (pp 117-118)
LRI. SSTfs, genital inlections, restricted to non-gonococcal. oro-dental and
arc cxcrcled in bfu,omIiand'\b"r"",mco,mmjii1ik'OA'3~~~~
l.
~~~~tl~o~~t~lt~~r~~11 ~~~l~tt~:r~~~:~h:~;~t~
e[a~,~~rr~:r~~j~i~~tt~mmcnded with ergot alkaloids. tcrfel1adinc. astemlzolc, cisapridc or pimozidc.
TH.IMD.07.11(02)
......
Clawan
-. .
0.5&
Claforan is indicated for the treatment
Gram-Positive
E. coli
Klebsiella spp.
Proteus mirabilis (Indole-negative)
Proteus spp. (Indole-positive)
H. injluenzae
Salmonella spp.
Citrobacter spp.
N. meningitidis
N. gonorrhoea
Branhamella catarrhalis
Serratia spp.
Providentia spp.
Morganella morganii
Enterobacter spp.
Streptococcus Group A. B
S. pneumoniae
S. epidermidis
S. aureus
Anaerobes
Peptococcus
Peptostreptococcus
Clostridium spp. (except C. diflicile)
Bacteroides spp. (including some
strains 01 B. ji"agilis)
l->11.h~rin.l110i'l:::lUlt~LfilJl~1Jlllmni'f11{h~v,H'lU"'un1J\!'irUU(1::::mnffl"irilrrum
lumlt\ll~hnJ('Ulm'\lYl <j.lff. 1075/2550
TH.IMD.07.11(02)
,
•
Dosage Recommendations
Premature babies and newborns
1
50 mg/kg/day
in 2 doses
Infants and children up to 12 years old 50-100 mg/kg/day
Severe infections maximum
:..
150-200 mg/kg/day
in 2-4 doses
in 3-4 doses
C'IIlJ*lrio.:OjgC1,a(O)faIl«'Cll:lUlSOJNICdClW.lIIX'IOdI..mtorrrspon.li1lJ1oOJICrfob.llm.:.I.O,i-l.1afor:uJtOIIlalll$l.MFCd"o:.u.mx$OJlIllJlCQl'l"~1010;
CdOU>.imc.20ICb(onnfOOUiN2096lccrClW.lmc~wn~IrI$I020ICc{ou.,imc
10d>(arif<u:ln(tdiOClS,rrt$p~·tncllt>("~ofENT.1n{«llllltJo{
l:iJDc)"'lIr1IW)·UXIand'cpI"oducl'\·ccqwinclU(!lO'IlOOO'Tbou.SqltICanlUl.Ent»."Mllnu..mc~u:gtfi,
InrcttlOft)ofbotl<1..tf""IU.llm...s)Ol\rr~AbJDrrull&llll(ccticcll
rOlpmoJltl1lJ\'tpropll)b.\lsirlpitintls"bozrcalinae~nlJc(tOIIlln(~JlldfOllbt~·LL,jsoflllfc(llOmlll~bt'nlS"'lthrtJuet,lttSisulJi:e.Coolralndlcallon:
~~~~~~~sor~;:~~~t~'~=~~h~Il~I~~~j,~g~~;~::;rl:=~~:~=:~~~'1:;;
IllOCIllOmlllll'3llnltS\l'Ca:NNlXOlIlIta:lly ..lI.b:anllllOll:l)W$.4:s.,\d\crwcrrl'(t:OlS ..'thall~aIlngJtl)~lU(hOlS!Janrt~!JOltJ.coMnopI>11
...... dn.i~(C\<:f.
~,·luiJ. trw.icnlICl.lC~ ~~' be ol&m-td. aW t=lICllI rue orSGOT Illll SGPT.nausa. \1llllIti~ abJownaI plNl andJ..atrtle1n:ayoo.'"lII. L,li=NIOr}' .mWlOl1-.!
poamal1he'I:CO('~ l.IIICDctiolll:b)·&larlllimllic....:-reuon.lbcroll(lll'TmI~ofl'robctxf'ldanrn:asn.lbcknllllg,u~~aodproloctpduraboao(
CWcna A falk poolb\'t r~t fcc rhc Coombs' tal =)"",."111' J)O"IC:doA.c. mo,k aad (~"yof adIrumilnl_&pcnd OltW j,f'\Wl:yoftbc illfa"lJOll.>lIl«pIiblbryoi'
the paUq.·nlull<icc.-d,tion ofl!lc 1"I>ml.l'rcmmJre 10fWICJ." rnutnMll $O~'\.. da) di'l4ed 10 2 obn.lor*=ltl..:l dlddrrn lIf'lO 12 )~old~ SG-IOO llIi kJ,'da)'wnJcld 1D 2·
~~~~"St=:ls:;c:::~~~~'=~~L~~=:::~:o!c21~ocrdu~~~~2~~2~~.~;;a"llOllS2.1~~
Kdc,clK'I':I.Pxbicllll<:f1l(lll
Further in/ormation (lyailable on requcst
sanofi-avenlis (Thailand! ltd.
87/2 eRe Tower 24/ h Floor, All Seasolls Place. Wireless Roml,
LlIInpi"i, Pot!llImwo/l, aangkok 10330, Thailand
Tel: 66(0) 2264 9999 Fox: 66(012264 9997
sanofi aventis
sanoFi pasteur
--
---
Thc vaccines division of sanofi-avcntis Group
TN' R-XGNT PR-G "T
5
~"
DX:i'A:i':i
• Diphtheria
• Poliomyelitis
AGAXtf:iT
G"'
• Tetanus
• Pertussis
• Haemophilus influenzae type b
PENIAXIM ADSORBED DIPHTHERIA, TETANUS. ACEllULAR PERTUSSIS, INACTIVATED POLIOMYELITIS VACCINE AND CONJUGATE HAEMOPHILUS INflUENZAE TYPE b VACCINE COMPQsmON The te:UYe Ingledle1lll
at,
n '1ItI1ows : Diptrlhe:na toxoid > 30 LU. Tetanus taxoo > 40 l..U,
Bortletella pertunll andgens : Toxoid 25 micrograms Rtamentous ttaemaoglulinkl 25 mlctoorams lnadMted pOIlOmyefitlS ytrus I'ype 1 40 O.U: Inaaiv3led pOUomyeIllls virus Iype 2 8 O.U: lnactJVa!ed pcAtomydilis virus I'fPe 3 32 O.U: HaernophikJs ifIfIumzae type b potysac:cI"laM
conjugaled wtth Tetanus proleln 10 microgram9 lor ooe 0.5 ml dose alllr f8C0nsUlution • O.U.: 0 anllgen unit. 0( eQuNi1lefIt quantity of II'1Do&n dNfmilled u~ 3 witablo Imml.H1Odlemlc:al memocs. The otht1lno~ are SLIO'ose. trometamoI. aIun'li'IIkrn hydrmQde. phe1IoI red . free Hanks
In;erc:tion In 0.5 mf pre·filed fYMoe$ In bOxt$ Of 1 Of 20. PfHTAXJM is RticaIed to ~ PfO:ect )'OUr cM:f
I7lIhe Haemophilus 1nltuenz3e rypo lJ baCterium (menJnom, b600cJ 1n1eeUOn. etc.) In ChildtJl'l 'rom 2 monthS of aoe, II does 'nOC prated ~ Intectiorts due to 0Chet typeS of ~ Inl\.Ienlae or
other mlcro-ofaanlsfT'la, 2. INFORMATION REQUIRED BEFORE USlf'JG PENTAXIM Do not .". PfHTAXIM : H your ctlifd sutfers 'rom COfMdSanI or non·eoowtsanr proor~ ~ (neurologic:al disease).• jf )'ClUr mKJ has experienoed a strono reacfun
medium. lormakl'etlyde. pneooxyethanol ana water lor InteetiOns. I. WHAT JS PENTAXIM AND WHEN IS IT USED? PEHTAX.IM IS ptesented In the form 01 a powdet 800 ISUSptflSiOn '01
agall1Sl dipntherQ. letIflU9. pelf1JS$I$, pollomyeSltis and ~nst 1nv.1StYe Inlectlon5 caused
ag3inil menlngms caused by
occur~
within 48 hours loUowino a previous vacclnatlOO: lever aboYe or equal fa 40?C. perSISlenJ crylog syndrome, lebriie or norHebrile coovubfoo, hypotnoltS • hoJpofC3dMy 6yndrome.l1 your dUId has
tetallus, pertussis. poIiomyerrtis and Haemoptulus inlluenzae
rype b InledJons.1f your dlild is
aIie~OIe to
route (the needle musl nol enter a blood vessel) or by the Imrad8fmal rOUI!. vaccMatlon lhould be poItponed In ehlldf80 sullerina Irom ltwf
a previooS"tacdnallon. it 15 partJeulafty Important 10
ThIS vacelno
may bo admlnisteff.d
a{
mon~o(
~ <WI
allergic /ll3CtIOn appearing aI1er a
the aetlw IllQfedl«llJ, iIt1Y 01 the exdpienf1. neomycin, streplor'l"ltfdn rod P'*Imlxln S, Tiki sptdll PflK:lIIt:IonI wtth PEMTAXJM : ensure thai
Of
pnMOlIS
w vacctne
vaeana1ion
~
diphtheria
IS not irIjcc1ed Dy Ihu ifTtJao.'3SClJW
acute diStalO. par1iWfafty inledJool; disease Of Pfoore&$IYe et'Ironic dISeaSe. sJ your child has a history 01 te.brile COf'IYU~ nol refa!ed 10
lhe hlmpetalure In !he 48 houl'5 following: lhe vaccination and admlnlsU'r an antipyretic IrtallJ1«l'l to reduce the lever rooulafty lor 48 hOUfS, Un
at e.ldpJenta
whit IInGwn e1fedl : FomukJefryde Use of oCfllr PcellMti :
the same time as ROR VJU{ vaccine Of HB,VAX DNA 5 10/115 mI vaec:tM. bill at two ~ sites. II )'OUr chad is 10 be Y3Cdnated with PfHTAXfM Md ~ 0Ch8t lhan those mtfl'IJOOed above at the gne Ii'ne. ask your doctor or your ptlarrnactst for
fOO(ll InformatIOn. Inform your doctor or your pharrNCl$l II your child i5 taking or llas taken ~ oltlef
moalcinal produC!.
even In tOe case Of non·presa1pllon rnedidn3l prOOuCtS. 3. HOW TO USE PENTAXIM ? POIOJogy ; The ~ recommended SChedule lodudes a Pf'a'naIy vaccination In 3
injectiona one or Two monUl Inrorval from 2 monlhs 01 age. fOl!clWed by a bOOSIer Ir1jectiOn during me second yfW 01 1110. Admlnlstr8Uon melhod :
Sanofi Pasteur Limited 87/2 CRC Tower 23
rd
Floor, All Seasons Place Wireless Road, Lumpini, Pathumwan Bangkok 10330
Tel: +66 (0) 2264 9999 Fax: +66 (0) 2264 8800